Next Article in Journal
MicroRNAs and Sepsis-Induced Cardiac Dysfunction: A Systematic Review
Next Article in Special Issue
Neurotransmitter Release Site Replenishment and Presynaptic Plasticity
Previous Article in Journal
New Strategies to Overcome Present CRISPR/Cas9 Limitations in Apple and Pear: Efficient Dechimerization and Base Editing
Previous Article in Special Issue
REDD1 Is Involved in Amyloid β-Induced Synaptic Dysfunction and Memory Impairment
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

The Signaling Pathways Involved in the Anticonvulsive Effects of the Adenosine A1 Receptor

1
4Brain, Department of Head and Skin, Ghent University, 9000 Ghent, Belgium
2
Department of Neurology, General Hospital Sint-Jan Bruges, 8000 Bruges, Belgium
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2021, 22(1), 320; https://doi.org/10.3390/ijms22010320
Submission received: 14 November 2020 / Revised: 22 December 2020 / Accepted: 27 December 2020 / Published: 30 December 2020

Abstract

:
Adenosine acts as an endogenous anticonvulsant and seizure terminator in the brain. Many of its anticonvulsive effects are mediated through the activation of the adenosine A1 receptor, a G protein-coupled receptor with a wide array of targets. Activating A1 receptors is an effective approach to suppress seizures. This review gives an overview of the neuronal targets of the adenosine A1 receptor focusing in particular on signaling pathways resulting in neuronal inhibition. These include direct interactions of G protein subunits, the adenyl cyclase pathway and the phospholipase C pathway, which all mediate neuronal hyperpolarization and suppression of synaptic transmission. Additionally, the contribution of the guanyl cyclase and mitogen-activated protein kinase cascades to the seizure-suppressing effects of A1 receptor activation are discussed. This review ends with the cautionary note that chronic activation of the A1 receptor might have detrimental effects, which will need to be avoided when pursuing A1 receptor-based epilepsy therapies.

1. Introduction

Epilepsy is a chronic brain disease ranking among the most common neurological disorders with an estimated prevalence of around 1% worldwide [1,2]. First-line treatment consists of pharmacotherapy with anti-epileptic drugs. Despite the development and approval of more than 20 new drugs over the past few decades, about one third of all epilepsy patients cannot be effectively treated this way [3,4]. This significant proportion of patients suffering from drug-resistant epilepsy has been an important drive for the search for new and better epilepsy treatments. In this regard, a lot of research has focused on the role of adenosine in epilepsy, owing to its ability to act as an endogenous seizure terminator and its potent anticonvulsive effects [5,6,7]. A great deal of studies have examined the mechanisms behind the anti-epileptic effects of adenosine and demonstrated that adenosine or adenosine analogues are effective in suppressing epileptic seizures, and this mainly through activation of adenosine A1 receptors. Several excellent reviews have been published in recent years describing the current knowledge on the role of adenosine in epilepsy and its therapeutic potential (see references [8,9,10]). The aim of this review is to specifically focus on the inhibitory A1 receptors and their downstream signaling pathways, giving an overview of the consequential neuronal effects and how these effects contribute to the seizure suppressing role of adenosine.

2. Adenosine in the Central Nervous System

Adenosine is a purine ribonucleoside fulfilling an important role in many physiological processes [11]. It has a general homeostatic role as modulator of cellular metabolism, but in the central nervous system (CNS) it also distinctively functions as a neuromodulator [12]. Adenosine is involved in various neural processes, including the regulation of sleep, arousal, nociception and respiration [13,14,15,16].
Adenosine is constitutively present at low concentrations in the brain, with basal extracellular adenosine levels kept in the range of 50–200 nM through enzymatic control [17]. The main source of adenosine in the brain is the intra- and extracellular breakdown of adenine nucleotides by 5′-nucleotidases (Figure 1). Adenine nucleotides released in the extracellular space, such as adenosine triphosphate (ATP) or adenosine monophosphate (AMP), are rapidly converted to adenosine [18]. Intracellularly, the formation of adenosine is linked to the energy consumption of the cell. An increase in cellular workload and in degradation of cytoplasmic ATP leads to increased formation of adenosine, with small intracellular changes in the concentration of ATP resulting in substantial changes in adenosine concentrations relative to its basal levels [12,19]. Adenosine formed intracellularly then exits the cell via equilibrative nucleoside transporters (ENTs), which allow for bidirectional passive transport of adenosine according to the concentration gradient. This way, extracellular adenosine concentration is mainly regulated via two intracellular enzymes: adenosine deaminase (ADA), which catabolizes adenosine to inosine, and adenosine kinase (ADK), which phosphorylates it to AMP [17,20]. Under physiological conditions, ADK is the main regulator of adenosine concentrations, but when concentrations increase in case of energy imbalance ADA exerts a more important role [21].
Extracellular adenosine exerts its modulatory effects via binding to G protein-coupled receptors (GPCRs), of which four subtypes have been characterized: A1, A2A, A2B and A3. These subtypes possess different affinities for adenosine and couple to specific G proteins. The adenosine A1 receptor (A1R) couples to Gi and Go proteins, the adenosine A2A receptor (A2AR) couples to Gs and Golf proteins, the adenosine A2B receptor (A2BR) couples to Gs and Gq proteins and the adenosine A3 receptor (A3R) couples to Gi and Gq proteins [20]. The A1 and A2A subtypes are high affinity receptors, with the A1R possessing the highest affinity for adenosine. They are the most abundantly expressed adenosine receptors in the CNS, while the A2BR and A3R have much lower affinities and are only expressed there in comparatively small numbers [13]. Highest CNS expression levels of the A1R are found in the neocortex, hippocampus, thalamus, cerebellum and spinal cord. The A2ARs on the other hand are predominantly expressed in the striatum [22].

3. Role of Adenosine in Epilepsy

Epilepsy is characterized by the generation of recurrent, unprovoked seizures [23]. These epileptic seizures are disruptions of neurological function caused by excessive or hypersynchronous neuronal activity and can be seen as the consequence of an imbalance between excitation and inhibition in the brain [24]. Excessive excitation and/or deficient inhibition leads to uncontrolled firing of neurons, which causes great metabolic stress during seizures. Consequently, adenosine levels rise and, because of its homeostatic role, adenosine responds as an endogenous anticonvulsant to counter this neuronal hyperactivity.
This link between adenosine and epilepsy was initially discovered 40 years ago. Studies focused on the involvement of adenosine in the regulation of cerebral blood flow showed an increase in adenosine levels during bicuculline-induced seizures [25,26]. Around the same time, the anticonvulsive properties of adenosine were demonstrated for the first time in vitro, in a hippocampal slice model [5], which triggered a wave of studies that confirmed the anticonvulsive effects of adenosine or adenosine analogues both in vitro [27] and in vivo [6,28,29]. The increase in adenosine concentrations during seizures was later also demonstrated in human patients with epilepsy using microdialysis [7]. Here, adenosine was found to reach levels high enough to suppress epileptiform activity in vitro and its concentrations remained elevated for the entire postictal period. These findings further supported the hypothesis that adenosine acts as an endogenous anticonvulsant and seizure terminator.
Soon after the first demonstration of the anticonvulsive properties of adenosine, the importance of A1Rs in mediating these effects was suggested [28]. In vitro electrophysiological studies showed that A1Rs were responsible for the inhibitory neuromodulatory effects of adenosine [30,31]. In various in vivo studies A1R agonists suppressed electrically or chemically induced seizures while A1R antagonists conversely aggravated seizure activity [32,33,34,35,36]. Furthermore, the potency of adenosine analogues as anticonvulsants was found to be positively correlated with their affinity for the A1R [37]. Besides studies demonstrating the anticonvulsant effects of exogenous activation of A1R, experiments with transgenic A1R-knock out animals delivered proof of the importance of endogenous adenosine acting on A1Rs. Deletion of A1Rs in mice leads to spontaneous seizures, increased spreading of induced seizures, aggravated seizure-induced brain damage and even the development of lethal status epilepticus [38,39,40].
Changes in the expression levels of A1Rs after seizures also further underline their relevance in relation to seizures and epilepsy. In acute seizure models, there is a clear upregulation of A1R expression in a matter of hours after the induction of seizures [41,42,43]. This shows that in an initial response to seizures, there is a potentiation of the anticonvulsive effects of the adenosinergic system by increasing the amount of A1Rs. However, the long-term modifications in chronic epilepsy are less straightforward. Multiple studies present contradictory results regarding changes in A1R expression in chronic epilepsy (Table 1). In temporal cortex biopsies from temporal lobe epilepsy (TLE) patients, both increases and decreases in A1R density have been reported [44,45]. In the latter case, however, biopsies of epileptic cortex were compared to control tissue of post-mortem human brains [45]. Initial studies in chronic seizure models indicated that brain structures affected by seizures displayed a decreased expression of A1Rs [46,47,48]. However, later studies also found increases in A1Rs and A1R mRNA in the epileptic brains of kindled animals [49,50]. The exact reason for these conflicting results remains unclear, they could be in part due to methodological differences between the studies. Nevertheless, it is evident that changes in the expression of A1Rs must play a role in epilepsy. An increase in A1Rs in case of chronic seizures could, similarly to the response to acute seizures, indicate the presence of an endogenous adaptive mechanism to limit the hyperexcitability of epileptic networks. On the other hand, reports of the loss of A1Rs after repeated seizures have led to the hypothesis that, together with maladaptive changes in the metabolism of adenosine (e.g., the overexpression of astroglial ADK [51]), this impairment of the inhibitory modulatory adenosine system is an important aspect in the development and progression of chronic epilepsy. Despite a possible decrease in A1R expression levels, administration of A1R agonists in chronic epilepsy models is still able to produce robust anticonvulsive effects [36,52]. It is thus very clear that inhibitory A1Rs are largely responsible for the contribution of adenosine in epilepsy. For this reason, the following sections of this review will focus on this adenosine receptor subtype.

4. A1R Structure, Activation and Expression

The A1R, together with the other adenosine receptors, belongs to the GPCR superfamily and is further classified into the α subfamily of the rhodopsins (formerly called “class A” of the GPCR superfamily) [53]. It is a glycoprotein with a molecular mass of ~36 kDa and, like all GPCRs, consists of 7 transmembrane α-helices, 3 extracellular and 3 intracellular loops, an extracellular N-terminus and an intracellular C-terminus [53,54]. The first four transmembrane domains of the A1R, (from the N-terminus to the end of the second extracellular loop) have been shown to be important for ligand binding and conferring specificity for A1-selective agonists/antagonists [55]. More recently, the determination of the crystal structure of the A1R in its inactive state has confirmed that conformational differences in these regions, especially the distinct conformation of the second extracellular loop, could underlie the selectivity of ligands for the A1 subtype [56]. Binding of an agonist to the A1R induces structural changes leading to receptor activation. The overall activation process is similar for all GPCRs and involves the relative rearrangement of transmembrane helices. A key transition during activation is the outward movement of the intracellular part of the transmembrane helix 6 (Figure 2), which has been observed in multiple GPCRs including the adenosine-bound A1R [57]. This opens up the cytosolic side of the receptor and enables interaction with G proteins, resulting in a ternary complex between agonist, receptor and G protein. Experiments with fusion proteins of the A1R and G protein subunits have indicated that receptor activation is the rate-limiting step in this ternary complex formation, rather than the interaction between the activated receptor and the G protein [58]. The kinetics of this activation process have been studied by looking at conformational changes with fluorescence resonance energy transfer (FRET) sensors. In these studies, receptor activation times were indirectly measured in various GPCRs and were found to be in the range of 30–50 ms [59].
The gene coding for the human A1R is located on the long arm of chromosome 1 and contains two separate promotors; A and B [60,61]. This results in two distinct transcripts of the A1R gene: transcript α produced by promoter A and transcript β produced by promoter B. Transcript β is found in all tissues expressing A1Rs while transcript α is only seen in tissues with high levels of A1R expression, such as the brain, testis and kidney [61]. This is due to multiple AUG codons in the 5′-untranslated region of transcript β which hinder protein expression at the post-transcriptional level [62]. In the CNS, A1Rs are most abundant in neurons, but A1Rs are also expressed by astrocytes, microglia and oligodendrocytes [63]. Receptor distribution varies per region, with the highest densities of A1Rs being found in the hippocampus [64]. The subcellular localization has been investigated in rat hippocampal neurons, where A1Rs are present extrasynaptically on the membrane of cell bodies, axons and dendrites and synaptically in the active zone of presynaptic terminals and at the postsynaptic density [65,66,67,68].

5. A1R Signaling

5.1. Coupling to G Proteins

G proteins are heterotrimeric complexes composed of a nucleotide-binding α-subunit (Gα) and a dimer containing the β- and γ-subunits (Gβγ). In its inactive state Gα is bound to guanosine diphosphate (GDP) and forms a stable complex with Gβγ. Activated GPCRs can interact with inactive G proteins and catalyze the release of GDP from the Gα subunit, which is rapidly replaced by guanosine triphosphate (GTP). This induces the dissociation of the heterotrimeric complex from the GPCR and a separation of the subunits. The GTP-bound Gα subunit, now in its active state, and the Gβγ subunit are then both free to interact with downstream effectors. Gα, which possesses intrinsic GTPase activity, hydrolyzes the bound GTP to GDP, terminating the signal. Then, Gβγ can be recruited and the inactive heterotrimeric complex is formed again (Figure 2) [69]. According to this traditional model of G protein signaling, there is a physical dissociation of Gα and Gβγ upon activation. Some studies point at a rearrangement rather than a dissociation of Gα and Gβγ subunits upon receptor activation. For example, Bünemann et al. found an increase in FRET signal upon receptor activation in living cells instead of the expected decrease if Gα and Gβγ subunits would dissociate [70].
G proteins are usually grouped into four main classes based on similarities between the Gα units: Gs, Gi/o, Gq/11 and G12/13 [71]. These classes distinctively affect specific second messenger pathways. A1Rs couple to several members of the pertussis toxin (PTX) sensitive Gi/o group, namely Gi1, Gi2, Gi3 and Go1 [72,73]. Gi proteins are named in accordance with their inhibitory effect on adenyl cyclase. The Go protein was discovered later, during the purification of Gi proteins, and was named as the ‘other’ GTP-binding protein. It is now known that Go is 5 to 10 times more abundant than other Gi proteins and is the most abundant G protein in the CNS [74]. It is worth noting that A1Rs can also interact with other G proteins. In Chinese hamster ovary (CHO) cells, the A1R can also activate GS and Gq proteins depending on the agonist used [75]. It has been suggested that agonist-specific conformations of the receptor lead to differential activation of Gi/o, Gs or Gq. Yet, coupling to Gi/o proteins remains the most prominent way of A1R signaling and the neuronal inhibitory effects of A1R activation are thus traditionally viewed to be mainly mediated by this group of G proteins.

5.2. Adenyl Cyclase and Phospholipase C

When A1Rs are being discussed in literature, their effects are mostly commonly attributed to downstream activation of two major signaling pathways: the adenyl cyclase (AC) pathway and the phospholipase C (PLC) pathway [11,22,76]. The former is the most prominent and well-known A1R–dependent signaling pathway: A1R activation leads to inhibition of AC and as a result less ATP is converted to the second messenger cyclic AMP (cAMP). Cyclic AMP activates protein kinase A (PKA) which then phosphorylates numerous proteins, including several transcription factors such as the well-studied cAMP response binding protein (CREB) [77]. The inhibition of AC by Gi/o-coupled receptors is mediated via Gαi subunits, but not by the α- subunit of the more abundant Go proteins [74]: purified GTP-bound Gαi1, Gαi2 and Gαi3 units can suppress AC activity, while Gαo cannot [78]. This was also confirmed in a later experiment with mutationally activated Gα units, where Gαi1, Gαi2, Gαi3 but not Gαo inhibited cAMP accumulation [79].
Regulation of the PLC pathway by A1Rs is less straightforward as there are both reports of A1R-dependent stimulation and inhibition of PLC activity. Phospholipase C enzymatically cleaves the membrane phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2) into diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3), which both function as important second messengers [80,81]. Diacylglycerol activates protein kinase C (PKC), which phosphorylates a variety of intracellular proteins, while IP3 binds to IP3-gated calcium channels on the membrane of the endoplasmic reticulum. PIP2 regulates the activity of several membrane-bound ion channels, mostly increasing their activity [82]. By hydrolyzing PIP2, PLC thus regulates those channels in the opposite way.
Most often, it is stated that A1Rs activate PLC-dependent signaling [11,22,76]. Studies in a smooth muscle cell line (DDT1 MF2) showed increased formation of IP3 and DAG upon administration of a selective A1R agonist, increasing PKC activity and mobilizing intracellularly stored Ca2+ [83,84]. This positive modulation was confirmed in CHO cells transfected with the rat or human A1R gene [85,86]. These cells showed an increase in IP3 formation and Ca2+ mobilization in response to A1R agonists. When A1R-expressing cells are transfected with a scavenger of Gβγ the A1R induced increase in IP3 formation is abolished [87]. This is in line with earlier studies showing that purified Gβγ units directly regulate the activity of PLC [88,89]. However, studies investigating the inhibitory effects of adenosine with CNS-derived tissue found conflicting results. In accordance with the enhancing effect on PLC activity seen in non-neuronal preparations, A1R stimulation in guinea-pig cerebral cortical slices [90] and rat striatal slices [91] further augmented histamine-induced IP3 accumulation. Yet, in mouse cerebral cortical slices [92] stimulation of A1Rs resulted in decreased histamine-induced IP3 formation. Additionally, in rat hippocampal slices selective A1R agonists inhibit PLC basal activity through Gi/o proteins [93,94]. As will be discussed in the next sections, either an increase or decrease in PLC activity could mediate the inhibitory effects of A1R activation.

5.3. Main Inhibitory Effects

The inhibitory mechanisms through which A1Rs exert their anticonvulsive effect occur in two major ways: by decreasing the excitability of neurons via hyperpolarization and through suppressing neurotransmission.

5.3.1. Hyperpolarization

Hyperpolarization of neurons is considered one of the most important mechanisms contributing to A1R-mediated seizure suppression. Stimulation of A1Rs opens postsynaptic K+ channels resulting in potassium efflux. This increased K+ conductance decreases the membrane potential and antagonizes membrane depolarization, rendering neurons less excitable. This adenosine-induced hyperpolarization was already demonstrated in 1982 through intracellular recordings in rat hippocampal slices. The investigators already suggested an increase in K+ conductance as mechanism [95]. This suggestion was confirmed by several studies a few years later: under voltage clamp, adenosine elicited outward K+ currents in mouse striatal neurons and in rat CA1 hippocampal neurons [96,97]. The observed hyperpolarization, between 2 and 10 mV in amplitude, was relatively slow as the outward K+ current only peaked 1–2 s after adenosine application [96].
Explained in more in detail in the following sections, follow-up studies identified the specific channels responsible for this A1R-mediated outward K+ current such as G protein-coupled inwardly rectifying K+ (GIRK) channels and ATP-sensitive K+ (KATP) channels (Figure 3). Moreover, small conductance Ca2+-activated K+ channels and two-pore domain K+ channels were reported to be activated by A1R signaling, respectively, in retinal ganglion cells [98] and mitral cells [99].

GIRK Channels

Soon after discovering the adenosine-activated K+ current in striatal neurons, Trussel and colleagues reported this current to be dependent on PTX-sensitive Gi/o proteins and GTP [100]. This indicated that adenosine can also activate GIRK channels in neurons, as was already demonstrated for heart muscle cells. In rat CA3 hippocampal neurons adenosine-induced activation of GIRK currents could be blocked with A1R antagonists, while A1R agonists mimicked the hyperpolarizing effect of adenosine, indicating that A1Rs are mediating adenosine-induced activation of GIRK channels [101]. GIRK channels (also known as Kir3 channels) belong to a large family of inwardly rectifying K+ channels. The term ‘inward rectification’ refers to the property of these channels to conduct larger inward currents at membrane voltages negative to the K+ equilibrium potential (EK) than outward currents at voltages positive to this potential. Since the membrane potential of neurons under physiological conditions is positive to EK, the opening of Kir channels results in a small outward K+ current [102]. Four different GIRK subunits (GIRK1-4, or Kir3.1-4) are expressed in mammals and assemble into homo- or heterotetramers to form functional GIRK channels. In the brain, the subunits GIRK1-3 are the most common [103]. A wealth of research indicates that direct binding of Gβγ is mainly responsible for opening of GIRK channels upon G-protein activation [102]. For instance, in Xenopus oocytes only co-expression of GIRK with Gβγ units, but not with Gα, resulted in sustained GIRK channel activity [104]. As well, binding sites for Gβγ could be identified in the N- and C- terminal domains of GIRK1 subunits that are important in GIRK channel activation [105]. However, the Gα subunit plays an important regulatory role. Binding of Gαi/o affects receptor specificity so that only Gβγ dimers derived from Gi/o proteins can activate GIRK channels [106]. It also controls gating of GIRK channels, with Gα keeping the basal channel activity low [107,108]. Hence, A1R stimulation leads to the activation of GIRK channels in neurons via direct binding of both G protein subunits. Additionally, the PLC pathway is involved in regulation of GIRK channel activity. PLC reduces GIRK channel activity by depleting PIP2, which acts as a positive modulator of GIRK channels [103], and by inducing PKC-mediated phosphorylation of GIRK channels [109,110]. A1R activation in neurons can reduce PLC activity (see higher) and its inhibitory effects on GIRK channel function, resulting in a net inhibition of neurons.

KATP Channels

Similarly to the GIRK channels, signaling of A1Rs to KATP channels was first discovered in myocytes, soon followed by a study demonstrating that these channels also open in response to adenosine in CA1 hippocampal neurons of the rat [111]. Glibenclamide, a KATP channel blocker, suppressed the adenosine-induced hyperpolarization of these neurons. A later study in neurons of the substantia nigra delivered further proof that these channels are activated by the A1R: selective A1R agonists induced an outward K+ current sensitive to tolbutamide, another KATP blocker, while a selective antagonist abolished these effects [112]. KATP channels also belong to the Kir superfamily and conduct an inwardly rectifying K+ current that is inhibited by intracellular ATP. These hetero-octamer channels are composed of four Kir6 subunits (Kir6.1 or Kir6.2) and four sulfonylurea receptor (SUR) subunits (SUR1 or SUR2), with the Kir6 subunits forming the pore while the SUR subunits serve a regulatory role. Binding of ATP to the cytoplasmic domain of Kir6 subunits closes the channel [113]. When ATP concentrations drop, the channels open and hyperpolarize the cell membrane. This way, KATP channels generally respond to the metabolic activity of cells. However, the sensitivity to the ATP blockade can also be modulated by other proteins, allowing KATP channels to open in response to external signals regardless of major changes in ATP concentration. To date, the exact mechanism by which A1Rs modulate ATP gating of these K+ channels remains unknown. Studies in cardiac myocytes point at a role for Gi/o proteins as KATP channels could be activated by application of GTP-bound Gαi1-3 units when the channels were closed by intracellular ATP [78,114,115]. In one of these studies, the Gαo subunit was reported to have no effect [114], though in the other studies Gαo was just as effective as the Gαi units [78,115]. At high concentration the Gβγ subunit could also activate KATP channels, resulting in more potent effects compared to activation by equimolar levels of Gα units [78]. In cardiac myocytes, adenosine activates KATP channels through PLC-induced activation of PKC, which phosphorylates the Kir6.2 subunit resulting in increased opening probability of the K+ channel [116,117]. In neurons it has yet to be demonstrated that this signaling pathway plays a role in the A1R-mediated activation of KATP channels but it is likely that G-protein dependent second messenger pathways are also mediating KATP channel opening upon A1R activation. An increase in PLC/PKC activity is thus likely to be involved in the modulation of neuronal KATP channels. However, similar to GIRK channels, also inhibition of PLC activity by A1Rs (reported by some studies in neurons, cfr. Section 5.2) can potentiate KATP channel function since PIP2 increases the open probability of these channels [113]. Moreover, the AC/cAMP pathway could modulate neuronal KATP channels. One study has reported a cAMP-dependent modulation of KATP channels by adenosine in breathing neurons of the pre-Bötzinger complex [118]. The activity of these neurons displays a spontaneous respiratory rhythm, which is decreased by A1R stimulation and an accompanying increase in KATP channel activity. The effects of A1Rs on KATP channel and respiratory rhythm were neutralized by elevation of the intracellular cAMP concentration. These results suggest that inhibition of cAMP formation by A1Rs is involved in the activation of KATP channels, but so far this has not been studied in any other neuronal cells.

Small Conductance Ca2+-Activated K+ Channels

In retinal ganglion cells, small conductance Ca2+-activated K+ (SK) channels are mediating adenosine-evoked hyperpolarization next to GIRK channels [98]. Indeed, both a GIRK channel blocker (rTertiapin-Q) and a SK channel blocker (apamin) partially inhibited the outward current seen in whole-cell patch-clamp recordings. As their name implies, small conductance Ca2+-activated K+ channels are activated by an increase in intracellular calcium. Their high Ca2+ sensitivity is conferred by calmodulin, bound to the intracellular C terminus of the SK channel. Binding of Ca2+ to calmodulin induces opening of the channel, resulting in an outward K+ current [119]. The SK component of the A1R-induced current in retinal ganglion cells was blocked by IP3 receptor antagonists [98]. This would suggest that PLC-mediated formation of IP3 induces the release of Ca2+ from intracellular stores, which activates the SK channels.

Two-Pore Domain K+ Channels

A recent study reported that the adenosine-mediated hyperpolarization of mitral cells (projection neurons of the olfactory bulb) was partially blocked by two-pore domain K+ (K2P) channel inhibitors (bupivacaine and halothane) [99]. This is a large family of background K+ channels which stabilize the negative resting membrane potential. A functional K2P channel consists of two subunits, each of which contains two pore domains (hence the name). The activity of these channels is regulated by a wide variety of parameters; some respond to changes in pH or temperature for example [120]. However, some subfamilies of K2P channels are also known to be regulated by GPCRs. For instance, stimulation of the PLC pathway by Gq-coupled receptors inhibits TASK (TWIK-related acid-sensitive K+ channel) and TREK (TWIK-related K+ channel) subfamilies, but activates channels of the TRESK (TWIK-related spinal cord K+ channel) subfamily. TREK channels are also inhibited by an increase in cAMP, which is counteracted in case of Gi signaling [121]. However, the specific subtype of the K2P channels that were activated by A1Rs in the study on mitral cells could not be identified and thus the pathway responsible for their activation is not known.

5.3.2. Suppression of Synaptic Transmission

Besides dampening neuronal excitation through opening of potassium channels, presynaptic and postsynaptic A1Rs also antagonize excitation by directly modulating the synaptic transmission (Figure 4). Presynaptically, A1R stimulation reduces the release of glutamate and other neurotransmitters in a Ca2+-dependent and -independent manner. Postsynaptically, A1R stimulation interferes with the function of NMDA (NMDARs) and AMPA receptors (AMPARs), both ionotropic glutamate receptors mediating fast excitatory neurotransmission.
The following paragraphs of this section will focus on excitatory neurotransmission. Nevertheless, it should be mentioned that A1Rs have also been found to reduce inhibitory GABAergic transmission in several brain areas [122]. Such modulation of GABAergic transmission could act as a complementary mechanism to control excitation of neuronal circuits. For instance, A1Rs have been demonstrated to suppress tonic GABAergic inhibition of interneurons in the hippocampus [123]. Disinhibition of these interneurons results in increased inhibition of pyramidal neurons, thus contributing to a decrease in hippocampal network excitability [124].

Inhibition Ca2+-Dependent Neurotransmitter Release

Besides modulation of K+ channels, the effects of A1Rs on presynaptic Ca2+ channels are probably the best known explanation for the inhibitory/anticonvulsive effects of these receptors. Action potentials reaching the presynaptic terminal trigger opening of voltage-gated Ca2+ channels (VGCCs) and the strong transient increase in intracellular Ca2+ nearby the VGCC (Ca2+ microdomains) triggers exocytosis of synaptic vesicles and neurotransmitter release [125]. Activation of A1Rs suppresses this evoked neurotransmission by inhibiting the Ca2+ influx via VGCCs.
VGCCs are Ca2+ channels that open in response to large (high-voltage activated; HVA channels) or small (low-voltage-activated; LVA channels) depolarizations of the membrane potential. All VGCCs are composed of a pore-forming and voltage-sensitive α1 subunit, consisting of four transmembrane domains. In case of HVA channels, the α1 subunit co-assembles with ancillary α2δ and β subunits. LVA channels, on the other hand, function as monomeric channels [126]. Based on differences in the α1 subunit, VGCCs are divided over three families: Cav1, Cav2 and Cav3. The Cav3 family makes up the group of low voltage-activated T-type Ca2+ channels, while Cav1 and Cav2 belong to the group of HVA channels. The Cav1 family exists of four different types of L-type Ca2+ channels (Cav1.1-1.4). The Cav2 family contains three members, each corresponding to a different type of VGCC: the P/Q-type (Cav2.1), the N-type (Cav2.2) and the R-type (Cav2.3) channels. The P/Q-type and the N-type channels are primarily responsible for the initiation of fast synaptic transmission and therefore closely interact with proteins of the synaptic vesicle release complex [126]. Specifically, these two VGCC types are inhibited by A1Rs.
Initial studies demonstrated reduced depolarization-evoked Ca2+ currents in the soma of neurons. The authors of these studies suggested this might be the mechanism for-adenosine-induced inhibition of neurotransmitter release if similar effects are present at synaptic terminals [127,128,129]. Indeed, studies in hippocampal slices confirmed that A1R agonists reduce presynaptic voltage-dependent Ca2+ currents at hippocampal synapses [130,131]. Pretreatment with ω-conotoxin GVIA (N-type VGCC blocker) attenuated the effect of adenosine on Ca2+ currents in superior cervical ganglion neurons and in hippocampal slices [129,131]. Interestingly, in these studies P/Q-type channels did not seem to play an important role since pretreatment of the neuronal preparations with ω-agatoxin IVA (P/Q-type VGCC blocker) did not result in any significant changes. However, later studies revealed that P/Q-type channels are also modulated by A1Rs at hippocampal synapses. The relative contribution of P/Q-type channels to an adenosine-induced decrease in Ca2+ current was similar to that of N-type channels at mossy fiber synapses [132]. Another study used ω-conotoxin MVIIC (another P/Q-type blocker) together with ω-conotoxin GVIA in hippocampal synaptosomes to demonstrate the role of P/Q-type and N-type channels [133]. When using a combination of both blockers, adenosine could even further decrease the release of glutamate at hippocampal nerve terminals, suggesting other non-identified VGCCs or other mechanisms (as will be discussed below) may also be involved.
Early studies demonstrated that the activation of PTX-sensitive Gi/o proteins is essential for the effects of adenosine on VGCCs and neurotransmission. Activation of G-proteins through the application of GTP-γS in chick sensory neurons mimicked adenosine-induced inhibition of Ca2+ currents [128], while PTX-based inhibition of Gi proteins abolished the inhibitory effects of adenosine on depolarization-induced Ca2+ currents in ganglion neurons [129] and glutamate release by cerebellar neurons [134]. Selective expression of Gβγ units mimicked the effects of Gi/o-coupled GPCRs on P/Q- and N-type channels indicating that Gβγ is directly involved in the inhibition of Cav2 channels [135,136,137]. The α1 units of these VGCCs indeed possess binding sites for Gβγ in the linker between domain I and domain II that, together with the N-terminal region, form an important interaction site with the Gβγ unit [138,139]. Binding of Gβγ to this interaction site stabilizes the closed conformation of the VGCCs. This direct form of inhibition by G proteins is voltage-dependent as strong membrane depolarization causes a brief dissociation of Gβγ from the channel [135].
Slower, voltage-independent regulation of VGCCs through G-protein mediated second messenger pathways are also in play. The PLC pathway increases P/Q- and N-type VGCC function through PKC-mediated phosphorylation of the domain I-II linker which antagonizes Gβγ-mediated inhibition of these VGCCs [138,140]. A1R-mediated inhibition of the PLC/DAG/PKC pathway reduces this antagonism and supports reduced VGCC activity. The activity of P/Q- and N-type channels is also modulated in two different ways by PIP2 [141]. Firstly, binding of PIP2 to a presumable high-affinity site stabilizes channel activity. Thus, depletion of PIP2 by PLC stimulation results in the closing of VGCCs. Secondly, by binding to another, low-affinity binding site, PIP2 would cause the VGCCs to be more reluctant to open, inhibiting currents evoked by small depolarizations. Interestingly, this inhibition is blocked by phosphorylation by PKA. This could explain the enhancement of P/Q- and N-type channel currents mediated by cAMP/PKA [142]. This demonstrates that the AC/cAMP/PKA pathway also regulates VGCCs to some degree.
At this moment, it is unclear to which degree the PLC/DAG/PKC and AC/cAMP/PKA pathways contribute to A1R-mediated inhibition of P/Q- and N-type channels. Two early studies could not demonstrate a role of the cAMP/PKA pathway in A1R mediated inhibition of VGCC in chick sensory neurons and mossy fibers [128,132]. Modulation of PKC activity did also not alter the effects of adenosine on Ca2+ currents in chick sensory neurons [128]. In entorhinal cortex (EC) slices, adenosine-mediated suppression of glutamatergic transmission is reduced after pretreatment with AC or PKA inhibitors, suggesting a significant contribution of AC and PKA inhibition to adenosine-induced suppression [143].

Decrease in Spontaneous Neurotransmitter Release

A1R signaling also suppresses neurotransmission in a calcium-independent way. When synaptic vesicles spontaneously fuse with the presynaptic membrane, they release small amounts of neurotransmitter which results in miniature postsynaptic currents (mPSCs). In hippocampal slices and cultured hippocampal neurons, the frequency of mPSCs is reduced by applying A1R agonists. This inhibition is not affected by Ca2+ blockers, indicating that A1Rs inhibit some component involved in vesicle release downstream from Ca2 entry [144,145].
Although phosphorylation of proteins of the vesicle release complex by PKA and PKC is known to play a role in Ca2+-independent regulation of neurotransmission, modulation of the AC or PLC pathways does not seem to be involved in the inhibition of mPSCs by adenosine [146,147]. For several other Gi/o-coupled GPCRs a crucial role for the Gβγ subunit in inhibiting mPSCs has been demonstrated [148]. For example, the injection of Gβγ in presynaptic terminals mimicked the inhibition of neurotransmission by serotonin without affecting Ca2+ influx and when a Gβγ inhibitor was injected the inhibitory action of serotonin was lost [149]. Through further investigation, it has been established that Gβγ subunits directly interact with and most likely block SNARE complex proteins which regulate fusion between synaptic vesicles and the synaptic membrane, thus inhibiting exocytosis [148].

Inhibition NMDAR Currents

In hippocampal pyramidal cells [150] and basolateral amygdala neurons [151], whole-cell patch-clamp recordings have shown that NMDAR-mediated currents are inhibited by application of A1R agonists. NMDA (N-methyl-D-aspartate) receptors are ionotropic glutamate receptors which exist as tetrameric channels composed of two GluN1 subunits along with two GluN2 or GluN3 subunits [152]. Receptor activation does not only require binding of glutamate, but also glycine binding and membrane depolarization for relief of the Mg2+ block. Opening of the channel allows influx of cations, including Ca2+ due to a high Ca2+ permeability. Ca2+ entry through NMDARs can initiate signaling cascades that lead to modulation of synaptic strength. This way, NMDARs not only mediate synaptic transmission but also synaptic plasticity [152]. In case of neuronal hyperactivity, however, excessive NMDAR stimulation can lead to maladaptive synaptic changes or to cell death due to extreme Ca2+ influx. By their inhibitory effect on NMDARs, A1R activation can prevent those deleterious Ca2+-mediated effects on top of reducing depolarizing currents.
NMDAR function is regulated by many postsynaptic GPCRs in a complex manner. For several of those GPCRs, such as dopamine receptors or GABA receptors, the molecular mechanisms behind the modulation have been well studied, showing that the signaling pathways involved are very variable between the different GPCRs [153]. Even receptors that couple to the same class of G proteins can have different effects on NMDAR activity; Gαi coupled receptors for example may potentiate or depress NMDAR function [154]. Regarding adenosine receptors, more is known about regulation via A2ARs, which have been reported to be able to both potentiate and inhibit NMDARs dependent on the cell type [153]. Though there is currently no direct evidence on the signaling pathways through which A1Rs inhibit NMDAR function, literature provides some indications. Firstly, PKA-induced phosphorylation of the C-terminal domains of GluN1 and GluN2 subunits increases NMDAR currents while blocking PKA activity decreases gating and Ca2+ permeability of NMDARs [155,156]. A1R-mediated inhibition of the AC/cAMP/PKA cascade could thus be responsible for the decrease in NMDAR currents. Secondly, PKC activity increases opening of NMDARs, reduces the Mg2+ block and increases channel expression at the cell surface via upregulation of SNARE-dependent exocytosis [157,158]. Therefore, in cells where A1R activation inhibits the PLC/DAG/PKC cascade, it is also likely to result in decreased NMDAR activity.

AMPAR Modulation

Modulation of AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors by the A1R has received less attention compared to NMDARs, even though AMPARs predominantly mediate fast excitatory transmission and antagonizing them results in more potent seizure suppression [159]. AMPARs are ionotropic glutamate receptors formed as tetramers from GluA1, GluA2, GluA3 or GluA4 subunits. Unlike NMDARs, most AMPARs are only permeable to Na+ and K+ ions and not to Ca2+. They only require binding of glutamate to open and cause depolarization of the membrane potential. While NMDARs possess a relatively stable expression at synapses, AMPARs are more dynamically expressed and can move into or out of the postsynaptic membrane. This variability in AMPAR expression levels is an important factor in the regulation of synaptic plasticity and is mediated by the Ca2+ influx caused by NMDARs [159].
A1Rs also modulate AMPAR trafficking independent from their effect on NMDARs. The phosphorylation of certain serine and threonine residues at the C-terminus of AMPAR subunits by several kinases, including PKA and PKC, plays an important role in AMPAR function and trafficking [160]. Especially PKA-mediated phosphorylation of Ser845 in GluA1 is key in AMPAR regulation. A1Rs maintain an inhibitory tone on Ser845 phosphorylation by inhibiting AC in several regions of the rat brain. Inhibition of A1R signaling under basal adenosine concentrations increases Ser845 phosphorylation and potentiates AMPAR currents while selective A1R activation reduces AMPAR currents in hippocampal slices [161,162]. Furthermore, it was also reported that A1Rs decrease the agonist affinity of AMPARs [162].
In addition, A1Rs can also reduce AMPAR expression through protein phosphatases (PP) which dephosphorylate the serine residues involved in receptor trafficking. A study in rat hippocampal slices demonstrated that GluA1 and GluA2 internalization after prolonged A1R stimulation is mediated by PP1, PP2A and PP2B using selective phosphatase inhibitors [163]. The signaling pathway for activation of phosphatases by A1Rs possibly involves mitogen-activated protein kinases (MAPKs) since PP2A is activated by p38 MAPK upon A1R stimulation [164,165] and inhibition of p38 MAPK and JNK (c-Jun N-terminal kinase) prevents GluA2 subunit internalization [166]. This signaling pathway will be discussed in more detail in the following section.

5.4. Other Signaling Pathways and Their Effects

The effects discussed above are the most well-known and major mechanisms by which the A1R leads to neuronal inhibition and anticonvulsant effects. They immediately affect neuronal excitability and are all mediated by the AC or PLC pathway and/or directly by G protein subunits. However, activation of A1Rs can result in several additional effects through activation of a variety of other signaling pathways. Below, we will outline a couple of other important pathways affected by the A1R, together with their relevance in the context of epilepsy.

5.4.1. Activation of MAP Kinases

MAP kinases are a protein family consisting of three main groups: the extracellular signal-regulated kinases (ERKs), the c-Jun N-terminal kinases (JNKs) and the p38 MAPKs/stress-activated protein kinases (SAPKs) [167]. These kinases are well known for their role in cell proliferation, cell growth and cell death, but they are involved in many more cellular functions. MAPKs are activated by various extracellular stimuli through a cascade of protein kinases; the MAPK kinases (MAPKK) and the MAPKK kinases (MAPKKK). The canonical pathway for activating MAPKs involves binding of mitogens (hence the name) or growth factors to receptor tyrosine kinases, followed by receptor dimerization and cross-autophosphorylation. This receptor phosphorylation triggers a signaling cascade via various intermediate proteins upstream from the MAPKKK.
GPCRs, including all adenosine receptors, can also activate MAPKs by tapping into this pathway [168]. All three groups of MAPKs are activated by A1Rs (Figure 5) [169,170], of which A1R-mediated activation of ERKs is best studied. It was first discovered in immortalized kidney fibroblasts (COS-7 cells) that ERK1 is activated by A1Rs (and other Gi-coupled receptors) via Gβγ subunits [171]. Further studies in CHO cells showed that Gβγ activates tyrosine kinase which then phosphorylates Shc. Phosphorylated Shc forms a complex with Grb2 followed by consecutive activation of Sos, Ras and c-Raf. c-Raf is the MAPKKK that leads to ERK1/2 activation [172]. However, this pathway cannot be generalized to all cell types since a study in a smooth muscle cell line showed that tyrosine kinase inhibition did not block A1Rs-mediated activation of ERK1/2, but phosphatidylinositol 3-kinase (PI3K) inhibitors did. [169]. PI3K could theoretically mediate JNK and p38 MAPK activation as well. Phosphatidylinositol 3,4,5-trisphosphate (PIP3), formed by PI3K, activates the guanine–nucleotide exchange factor Prex1 which in turn activates Rac [173]. Rac is a GTPase is involved in signaling cascades leading to JNK and p38 MAPK activation [174].
Activation of MAPK pathways by A1Rs most likely contributes to the seizure-suppressive effects of adenosine. JNK and p38 MAPK are involved in A1R-mediated suppression of synaptic transmission in the CA1 region of the hippocampus by mediating for example AMPAR internalization via activation of phosphatases (see AMPAR Modulation, Section 5.3.2) [166,175]. Furthermore, MAPKs are involved in protective mechanisms against seizure-induced cell death. Acute seizures in rats induce ERK and p38 MAPK activation in the hippocampus. Blocking these MAPKs aggravates neuronal degradation caused by a subsequent status epilepticus [176]. However, excessive activation of MAPK pathways can also cause negative effects. For instance, constitutive ERK activation increases NMDAR activity by augmenting GluN2 subunit protein levels. This increases neuronal excitability and results in epileptic seizures [177]. Additionally, MAPKs are implicated in epileptogenesis by affecting RNA-binding proteins. In this way, the overactivation of MAPKs can lead to aberrant expression of synaptic proteins [178]. Acute activation of MAPKs by the A1R could thus be beneficial, but overactivation becomes more detrimental.

5.4.2. Guanyl Cyclase Pathway

Another pathway activated by the A1R is the soluble guanylyl cyclase (sGC) or the nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) pathway. Nitric oxide release upon activation of nitric oxide synthase (NOS) activates sGC, which converts GTP to cGMP. The main effector of cGMP is protein kinase G (PKG). In the CNS, the NO/cGMP pathway exerts many functions including modulation of neuronal excitability and synaptic transmission [179,180].
By blocking NOS, sGC and PKG, Cascalheira et al. demonstrated that A1R-induced inhibition of neurotransmission in the CA1 region of hippocampal slices is partly mediated by the NO/cGMP pathway [181,182]. In cardiomyocytes, the activation of A1Rs stimulates NOS through activation of PLC and subsequent increase in Ca2+/calmodulin and PKC activity [183]. Moreover, the A1R-induced phosphorylation of p38 MAPK is prevented by inhibitors of the cGMP pathway, providing a link between A1R—induced activation of NO/cGMP and MAPKs [165]. It is yet to be determined whether these mechanisms apply to neurons as well.

5.4.3. Modulation of Nuclear Factor-κB and Brain-Derived Neurotrophic Factor

Stimulation of A1Rs can also produce more delayed effects by influencing gene expression. As an example, we will briefly discuss the effects of the A1R on the transcription factor nuclear factor-κB (NF-κB) and one of its target gene products—brain-derived neurotrophic factor (BDNF)—since these factors are involved in epilepsy.
NF-κB is an inducible transcription factor that regulates the expression of hundreds of genes involved in inflammation, immunity, cell survival and cell differentiation. NF-κB is present in the cytoplasm in an inactive state as long as it is associated with its inhibitor; IκB (inhibitor of κB). Phosphorylation of IκB triggers its ubiquitination and degradation and activation of NF-κB [184]. NF-κB activation can be initiated by a large number of environmental stimuli, such as bacterial products or UV light, as well as by a variety of GPCRs, including the A1R. It was shown, for example, that application of adenosine in rat basal forebrain slices increased the amount of NF-κB bound to DNA. This was significantly reduced by pretreatment of the slices with an A1R antagonist [185]. On a side note, NF-κB can also bind to the promoter sequence of the A1R gene and increase A1R expression [186]. The signaling pathway responsible for the activation of NF-κB by A1Rs is not yet clarified. In human lymphoblastoma and embryonic kidney cells [187], A1R-induced NF-κB activation was not mediated by Gi/o proteins but instead relied on G16, a G protein specific to hematopoietic cells [188]. Two cascades were found to be initiated by Gα16 and Gβγ: (1) activation of PLC, resulting in activation of PKC and calmodulin-dependent protein kinase II (CaMKII) due to increased Ca2+ concentration and (2) activation of the tyrosine kinase c-Src, which initiates a MAPK cascade leading to phosphorylation of ERK via Ras and c-Raf. All three kinases -PKC, CaMKII and ERK-can activate the IκB kinase (IKK) complex which phosphorylates IκB and releases NF-κB. Whether any of these pathways are involved in NF-κB activation in neurons remains to be studied.
In the CNS, NF-κB can have a neuroprotective role, but it is also involved in neurodegeneration. It is believed that a certain level of NF-κB is required to maintain normal neuronal functioning while too low or too high NF-κB levels are pathological [189]. Based on preclinical seizure models, it is not clear whether the activation of NF-κB by A1Rs could be beneficial or detrimental. In one rat study, inhibition of NF-κB increased susceptibility for kainic acid induced seizures [190]. However, another study in the same rat model showed a decrease in seizure susceptibility and also found that NF-κB inhibition resulted in decreased expression of P-glycoprotein [191]. NF-κB activation could thus lead to an elevated risk for seizures and increased P-glycoprotein expression, an important multidrug transporter implicated in drug-resistance in epilepsy. These conflicting results demonstrate the complexity of NF-κB signaling, owing to the many possible genes that can be induced by this transcription factor.
One of the genes which expression is affected by NF-κB is BDNF [192]. Induction of NF-κB activity in response to kainic acid administration increases the expression of BDNF both in vitro as in vivo [190,193]. A1R stimulation could thus result in upregulation of BDNF via NF-κB. This is supported by a recent study with A1R-knock out mice, where BDNF levels after seizure induction were lower in the knock out compared to wild type animals [194]. As neurotrophin, BDNF is important for the growth and survival of neurons during development. In the mature brain, the function of BDNF is less clear. BDNF has been reported to induce phosphorylation of GluN1 subunits of NMDARs, thereby increasing their activity [195]. In the context of epilepsy, indeed, most evidence indicates that BDNF increases neuronal excitability and contributes to epileptogenesis [196,197]. However, there is some evidence that BDNF can have a neuroprotective effect by increasing the expression of the inhibitory neuropeptide Y (NPY) [196,197]. Via its Gi/o-coupled receptors, NPY also inhibits several types of VGCCs and activates GIRK channels [198,199].

6. Conclusions

The importance of the A1R, through which the adenosinergic system exerts many of its anticonvulsive and neuroprotective effects, is well established. This review provided an overview of signaling pathways through which A1R activation yields those effects. The two principal inhibitory neuronal mechanisms of the A1R are well known; (1) membrane hyperpolarization caused by the activation of K+ channels and (2) suppression of synaptic transmission via inhibition of VGCCs and synaptic vesicle release (Figure 6). The second messenger systems and molecular mechanisms responsible for the activation or inhibition of these targets, however, remain to be completely unraveled, though evidence indicates important roles of the AC and the PLC pathways, along with the Gβγ subunit. Additional evidence indicates a role for the NO/cGMP pathway and the MAPKs in mediating the inhibitory actions of the A1R. Caution must be taken, however, as a major part of the evidence reviewed regarding A1R signaling is derived from studies in non-neuronal cells. Beyond acute anticonvulsive effects, it is important to consider that A1R activation can result in additional delayed and long-term neuromodulatory effects. These can have an opposite, detrimental effect and potentially aggravate seizure activity. Thus, when developing future epilepsy therapies based on A1R stimulation, the aim should be to evoke the immediate inhibitory effects of the A1R while avoiding the negative effects of chronic overstimulation.

Funding

During the writing of this review, Jeroen Spanoghe was supported by a project grant from the “Fonds voor Wetenschappelijk Onderzoek” (FWO), grant number G042219N.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

A1RAdenosine A1 receptor
A2ARAdenosine A2A receptor
A2BRAdenosine A2B receptor
A3RAdenosine A3 receptor
ACAdenyl cyclase
ADAAdenosine deaminase
ADKAdenosine kinase
AMPAdenosine monophosphate
AMPARΑ-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor
ATPAdenosine triphosphate
BDNFBrain-derived neurotrophic factor
CamKIICalmoduline-dependent protein kinase II
cAMPCyclic adenosine monophosphate
cGMPCyclic guanosine monophosphate
CHOChinese hamster ovary
CNSCentral nervous system
CREBcAMP response binding protein
DAGDiacylglycerol
ENTEquilibrative nucleoside transporter
ERKExtracellular signal-regulated kinase
FRETFluorescence resonance energy transfer
G protein α subunit
GβγG protein βγ subunit
GDPGuanosine diphosphate
GIRKG protein-coupled inwardly rectifying K+ channel
GPCRG protein-coupled receptor
GTPGuanosine triphosphate
HVAHigh-voltage activated
IKKIκB kinase
IκBInhibitor of IκB
IP31,4,5-triphosphate
JNKc-Jun N-terminal kinase
K2PTwo-pore domain K+ channel
KATPATP-sensitive K+ channel
LVALow-voltage activated
MAPKMitogen-activated protein kinase
MAPKKMAPK kinase
MAPKKKMAPKK kinase
mPSCMiniature postsynaptic current
NF-κBNuclear factor-κB
NMDARN-methyl D-aspartate receptor
NONitric oxide
NOSNitric oxide synthase
NPYNeuropeptide Y
PI3KPhosphatidylinositol 3-kinase
PIP2Phosphatidylinositol 4,5-biphosphate
PIP3Phosphatidylinositol 3,4,5-triphosphate
PKAProtein kinase A
PKCProtein kinase C
PKGProtein kinase G
PLCPhospholipase C
PPProtein phosphatase
PTXPertussin toxin
SAPKStress-activated protein kinase
sGCSoluble guanylyl cyclase
SKSmall conductance Ca2+-activated K+ channel
SURSulfonylurea receptor
TASKTWIK-related acid sensitive K+ channel
TREKTWIK-related K+ channel
TRESKTWIK-related spinal cord K+ channel
VGCCVoltage-gated Ca2+ channel

References

  1. Ngugi, A.K.; Bottomley, C.; Kleinschmidt, I.; Sander, J.W.; Newton, C.R. Estimation of the Burden of Active and Life-Time Epilepsy: A Meta-Analytic Approach. Epilepsia 2010, 51, 883–890. [Google Scholar] [CrossRef]
  2. Behr, C.; Goltzene, M.A.; Kosmalski, G.; Hirsch, E.; Ryvlin, P. Epidemiology of Epilepsy. Rev. Neurol. (Paris) 2016, 172, 27–36. [Google Scholar] [CrossRef]
  3. Golyala, A.; Kwan, P. Drug Develpment for Refractory Epilepsy: The Past 25 Years and Beyond. Seizure 2017, 44, 147–156. [Google Scholar] [CrossRef] [Green Version]
  4. Kwan, P.; Brodie, M.J. Early Identification of Refractory Epilepsy. N. Engl. J. Med. 2000, 342, 314–319. [Google Scholar] [CrossRef]
  5. Dunwiddie, T.V. Endogenously Released Adenosine Regulates Excitability in the In Vitro Hippocampus. Epilepsia 1980, 21, 541–548. [Google Scholar] [CrossRef]
  6. Dragunow, M.; Goddard, G.V.; Laverty, R. Is Adenosine an Endogenous Anticonvulsant? Epilepsia 1985, 26, 480–487. [Google Scholar] [CrossRef] [PubMed]
  7. During, M.J.; Spencer, D.D. Adenosine: A Potential Mediator of Seizure Arrest and Postictal Refractoriness. Ann. Neurol. 1992, 32, 618–624. [Google Scholar] [CrossRef] [PubMed]
  8. Boison, D. Adenosinergic Signaling in Epilepsy. Neuropharmacology 2016, 104, 131–139. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  9. Rombo, D.M.; Ribeiro, J.A.; Sebastião, A.M. Role of Adenosine Receptors in Epileptic Seizures. In The Adenosine Receptors; Springer International Publishing: Cham, Switzerland, 2018; Volume 34, pp. 309–350. [Google Scholar]
  10. Weltha, L.; Reemmer, J.; Boison, D. The Role of Adenosine in Epilepsy. Brain Res. Bull. 2019, 151, 46–54. [Google Scholar] [CrossRef]
  11. Sachdeva, S.; Gupta, M. Adenosine and Its Receptors as Therapeutic Targets: An Overview. Saudi Pharm. J. 2013, 21, 245–253. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Cunha, R.A. Adenosine as a Neuromodulator and as a Homeostatic Regulator in the Nervous System: Different Roles, Different Sources and Different Receptors. Neurochem. Int. 2001, 38, 107–125. [Google Scholar] [CrossRef]
  13. Dunwiddie, T.V.; Masino, S.A. The Role and Regulation of Adenosine in the Central Nervous System. Annu. Rev. Neurosci. 2001, 24, 31–55. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Franziska Reichert, C.; Cajochen, C.; Schmidt, C.; Cajochen, C. Sleep-Wake Regulation and Its Impact on Working Memory Performance: The Role of Adenosine. Biology (Basel) 2016, 5, 11. [Google Scholar] [CrossRef] [Green Version]
  15. Sawynok, J.; Liu, X.J. Adenosine in the Spinal Cord and Periphery: Release and Regulation of Pain. Prog. Neurobiol. 2003, 69, 313–340. [Google Scholar] [CrossRef]
  16. Lahiri, S.; Mitchell, C.H.; Reigada, D.; Roy, A.; Cherniack, N.S. Purines, the Carotid Body and Respiration. Respir. Physiol. Neurobiol. 2007, 157, 123–129. [Google Scholar] [CrossRef] [Green Version]
  17. Latini, S.; Pedata, F. Adenosine in the Central Nervous System: Release Mechanisms and Extracellular Concentrations. J. Neurochem. 2001, 79, 463–484. [Google Scholar] [CrossRef] [Green Version]
  18. Dunwiddie, T.V.; Dlao, L.; Proctor, W.R. Adenine Nucleotides Undergo Rapid, Quantitative Conversion to Adenosine in the Extracellular Space in Rat Hippocampus. J. Neurosci. 1997, 17, 7673–7682. [Google Scholar] [CrossRef]
  19. Fredholm, B.B. Adenosine, an Endogenous Distress Signal, Modulates Tissue Damage and Repair. Cell Death Differ. 2007, 14, 1315–1323. [Google Scholar] [CrossRef] [Green Version]
  20. Fredholm, B.B.; Ijzerman, A.P.; Jacobson, K.A.; Klotz, K.-N.; Linden, J. International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors. Pharmacol. Rev. 2001, 53, 527–552. [Google Scholar]
  21. Lloyd, H.G.E.; Fredholm, B.B. Involvement of Adenosine Deaminase and Adenosine Kinase in Regulating Extracellular Adenosine Concentration in Rat Hippocampal Slices. Neurochem. Int. 1995, 26, 387–395. [Google Scholar] [CrossRef]
  22. Benarroch, E.E. Adenosine and Its Receptors: Multiple Modulatory Functions and Potential Therapeutic Targets for Neurologic Disease. Neurology 2008, 70, 231–236. [Google Scholar] [CrossRef]
  23. Fisher, R.S.; Van Emde Boas, W.; Blume, W.; Elger, C.; Genton, P.; Lee, P.; Engel, J. Epileptic Seizures and Epilepsy: Definitions Proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005, 46, 470–472. [Google Scholar] [CrossRef] [PubMed]
  24. Stafstrom, C.E.; Carmant, L. Seizures and Epilepsy: An Overview for Neuroscientists. Cold Spring Harb. Perspect. Med. 2015, 5, a022426. [Google Scholar] [CrossRef] [PubMed]
  25. Schrader, J.; Wahl, M.; Kuschinsky, W.; Kreutzberg, G.W. Increase of Adenosine Content in Cerebral Cortex of the Cat during Bicuculline-Induced Seizure. Pflügers Arch. Eur. J. Physiol. 1980, 387, 245–251. [Google Scholar] [CrossRef] [PubMed]
  26. Winn, H.R.; Welsh, J.E.; Rubio, R.; Berne, R.M. Changes in Brain Adenosine during Bicuculline-Induced Seizures in Rats. Effects of Hypoxia and Altered Systemic Blood Pressure. Circ. Res. 1980, 47, 568–577. [Google Scholar] [CrossRef] [Green Version]
  27. Ault, B.; Wang, C.M. Adenosine Inhibits Epileptiform Activity Arising in Hippocampal Area CA3. Br. J. Pharmacol. 1986, 87, 695–703. [Google Scholar] [CrossRef] [Green Version]
  28. Dunwiddie, T.V.; Worth, T. Sedative and Anticonvulsant Effects of Adenosine Analogs in Mouse and Rat. J. Pharmacol. Exp. Ther. 1982, 220, 70–76. [Google Scholar]
  29. Barraco, R.A.; Swanson, T.H.; Phillis, J.W.; Berman, R.F. Anticonvulsant Effects of Adenosine Analogues on Amygdaloid-Kindled Seizures in Rats. Neurosci. Lett. 1984, 46, 317–322. [Google Scholar] [CrossRef]
  30. Dunwiddie, T.V.; Fredholm, B.B. Adenosine Receptors Mediating Inhibitory Electrophysiological Responses in Rat Hippocampus Are Different from Receptors Mediating Cyclic AMP Accumulation. Naunyn. Schmiedebergs. Arch. Pharmacol. 1984, 326, 294–301. [Google Scholar] [CrossRef]
  31. Lee, K.S.; Schubert, P.; Heinemann, U. The Anticonvulsive Action of Adenosine: A Postsynaptic, Dendritic Action by a Possible Endogenous Anticonvulsant. Brain Res. 1984, 321, 160–164. [Google Scholar] [CrossRef]
  32. Dragunow, M.; Robertson, H.A. 8-Cyclopentyl 1,3-Dimethylxanthine Prolongs Epileptic Seizures in Rats. Brain Res. 1987, 417, 377–379. [Google Scholar] [CrossRef]
  33. Franklin, P.H.; Zhang, G.; Tripp, E.D.; Murray, T.F. Adenosine A1 Receptor Activation Mediates Suppression of (-) Bicuculline Methiodide-Induced Seizures in Rat Prepiriform Cortex. J. Pharmacol. Exp. Ther. 1989, 251, 1229–1236. [Google Scholar] [PubMed]
  34. Von Lubitz, D.K.J.E.; Paul, I.A.; Carter, M.; Jacobson, K.A. Effects of N6-Cyclopentyl Adenosine and 8-Cyclopentyl-1,3-Dipropylxanthine on Induced Seizures in Mice. Eur. J. Pharmacol. 1993, 249, 265–270. [Google Scholar] [CrossRef]
  35. Abdul-Ghani, A.S.; Attwell, P.J.E.; Bradford, H.F. The Protective Effect of 2-Chloroadenosine against the Development of Amygdala Kindling and on Amygdala-Kindled Seizures. Eur. J. Pharmacol. 1997, 326, 7–14. [Google Scholar] [CrossRef]
  36. Gouder, N.; Fritschy, J.-M.; Boison, D. Seizure Suppression by Adenosine A1 Receptor Activation in a Mouse Model of Pharmacoresistant Epilepsy. Epilepsia 2003, 44, 877–885. [Google Scholar] [CrossRef] [Green Version]
  37. Zhang, G.; Franklin, P.H.; Murray, T.F. Activation of Adenosine A1 Receptors Underlies Anticonvulsant Effect of CGS21680. Eur. J. Pharmacol. 1994, 255, 239–243. [Google Scholar] [CrossRef]
  38. Fedele, D.E.; Li, T.; Lan, J.Q.; Fredholm, B.B.; Boison, D. Adenosine A1 Receptors Are Crucial in Keeping an Epileptic Focus Localized. Exp. Neurol. 2006, 200, 184–190. [Google Scholar] [CrossRef]
  39. Kochanek, P.M.; Vagni, V.A.; Janesko, K.L.; Washington, C.B.; Crumrine, P.K.; Garman, R.H.; Jenkins, L.W.; Clark, R.S.B.; Homanics, G.E.; Dixon, C.E.; et al. Adenosine A1 Receptor Knockout Mice Develop Lethal Status Epilepticus after Experimental Traumatic Brain Injury. J. Cereb. Blood Flow Metab. 2006, 26, 565–575. [Google Scholar] [CrossRef] [Green Version]
  40. Li, T.; Quan Lan, J.; Fredholm, B.B.; Simon, R.P.; Boison, D. Adenosine Dysfunction in Astrogliosis: Cause for Seizure Generation? Neuron Glia Biol. 2007, 3, 353–366. [Google Scholar] [CrossRef] [Green Version]
  41. Daval, J.L.; Sarfati, A. Effects of Bicuculline-Induced Seizures on Benzodiazepine and Adenosine Receptors in Developing Rat Brain. Life Sci. 1987, 41, 1685–1693. [Google Scholar] [CrossRef]
  42. Angelatou, F.; Pagonopoulou, O.; Kostopoulos, G. Alterations of A1 Adenosine Receptors in Different Mouse Brain Areas after Pentylentetrazol-Induced Seizures, but Not in the Epileptic Mutant Mouse “Tottering”. Brain Res. 1990, 534, 251–256. [Google Scholar] [CrossRef]
  43. Pagonopoulou, O.; Angelatou, F.; Kostopoulos, G. Effect of Pentylentetrazol-Induced Seizures on A1 Adenosine Receptor Regional Density in the Mouse Brain: A Quantitative Autoradiographic Study. Neuroscience 1993, 56, 711–716. [Google Scholar] [CrossRef]
  44. Angelatou, F.; Pagonopoulou, O.; Maraziotis, T.; Olivier, A.; Villemeure, J.G.; Avoli, M.; Kostopoulos, G. Upregulation of A1 Adenosine Receptors in Human Temporal Lobe Epilepsy: A Quantitative Autoradiographic Study. Neurosci. Lett. 1993, 163, 11–14. [Google Scholar] [CrossRef]
  45. Glass, M.; Faull, R.L.M.; Bullock, J.Y.; Jansen, K.; Mee, E.W.; Walker, E.B.; Synek, B.J.L.; Dragunow, M. Loss of A1 Adenosine Receptors in Human Temporal Lobe Epilepsy. Brain Res. 1996, 710, 56–68. [Google Scholar] [CrossRef]
  46. Ochiishi, T.; Takita, M.; Ikemoto, M.; Nakata, H.; Suzuki, S.S. Immunohistochemical Analysis on the Role of Adenosine A1 Receptors in Epilepsy. Neuroreport 1999, 10, 3535–3541. [Google Scholar] [CrossRef]
  47. Ekonomou, A.; Sperk, G.; Kostopoulos, G.; Angelatou, F. Reduction of A1 Adenosine Receptors in Rat Hippocampus after Kainic Acid-Induced Limbic Seizures. Neurosci. Lett. 2000, 284, 49–52. [Google Scholar] [CrossRef]
  48. Rebola, N.; Coelho, J.E.; Costenla, A.R.; Lopes, L.V.; Parada, A.; Oliveira, C.R.; Soares-da-Silva, P.; de Mendonca, A.; Cunha, R.A. Decrease of Adenosine A1 Receptor Density and of Adenosine Neuromodulation in the Hippocampus of Kindled Rats. Eur. J. Neurosci. 2003, 18, 820–828. [Google Scholar] [CrossRef]
  49. Tchekalarova, J.; Sotiriou, E.; Georgiev, V.; Kostopoulos, G.; Angelatou, F. Up-Regulation of Adenosine A1 Receptor Binding in Pentylenetetrazol Kindling in Mice: Effects of Angiotensin IV. Brain Res. 2005, 1032, 94–103. [Google Scholar] [CrossRef]
  50. Hargus, N.J.; Jennings, C.; Perez-Reyes, E.; Bertram, E.H.; Patel, M.K. Enhanced Actions of Adenosine in Medial Entorhinal Cortex Layer II Stellate Neurons in Temporal Lobe Epilepsy Are Mediated via A 1-Receptor Activation. Epilepsia 2012, 53, 168–176. [Google Scholar] [CrossRef] [Green Version]
  51. Boison, D. Adenosine Dysfunction in Epilepsy. Glia 2012, 60, 1234–1243. [Google Scholar] [CrossRef] [Green Version]
  52. Heidarianpour, A.; Sadeghian, E.; Mirnajafi-Zadeh, J.; Fathollahi, Y.; Mohammad-Zadeh, M. Anticonvulsant Effects of N6-Cyclohexyladenosine Microinjected into the CA1 Region of the Hippocampus on Entorhinal Cortex-Kindled Seizures in Rats. Epileptic Disord. 2006, 8, 259–266. [Google Scholar] [PubMed]
  53. Latek, D.; Modzelewska, A.; Trzaskowski, B.; Palczewski, K.; Filipek, S. G Protein-Coupled Receptors-Recent Advances. Acta Biochim. Pol. 2012, 59, 515–529. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Ren, H.; Stiles, G.L. Characterization of the Human A1 Adenosine Receptor Gene. Evidence for Alternative Splicing. J. Biol. Chem. 1994, 269, 3104–3110. [Google Scholar] [PubMed]
  55. Rivkees, S.A.; Lasbury, M.E.; Barbhaiya, H. Identification of Domains of the Human A1 Adenosine Receptor That Are Important for Binding Receptor Subtype-Selective Ligands Using Chimeric A1/A2a Adenosine Receptors. J. Biol. Chem. 1995, 270, 20485–20490. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  56. Glukhova, A.; Thal, D.M.; Nguyen, A.T.; Vecchio, E.A.; Jörg, M.; Scammells, P.J.; May, L.T.; Sexton, P.M.; Christopoulos, A. Structure of the Adenosine A1 Receptor Reveals the Basis for Subtype Selectivity. Cell 2017, 168, 867–877.e13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  57. Draper-Joyce, C.J.; Khoshouei, M.; Thal, D.M.; Liang, Y.L.; Nguyen, A.T.N.; Furness, S.G.B.; Venugopal, H.; Baltos, J.A.; Plitzko, J.M.; Danev, R.; et al. Structure of the Adenosine-Bound Human Adenosine A1 Receptor-Gi Complex. Nature 2018, 558, 559–565. [Google Scholar] [CrossRef]
  58. Waldhoer, M.; Wise, A.; Milligan, G.; Freissmuth, M.; Nanoff, C. Kinetics of Ternary Complex Formation with Fusion Proteins Composed of the A1-Adenosine Receptor and G Protein α-Subunits. J. Biol. Chem. 1999, 274, 30571–30579. [Google Scholar] [CrossRef] [Green Version]
  59. Lohse, M.J.; Maiellaro, I.; Calebiro, D. Kinetics and Mechanism of G Protein-Coupled Receptor Activation. Curr. Opin. Cell Biol. 2014, 27, 87–93. [Google Scholar] [CrossRef]
  60. Townsend-Nicholson, A.; Baker, E.; Schofield, P.R.; Sutherland, G.R. Localization of the Adenosine A1 Receptor Subtype Gene (ADORA1) to Chromosome 1q32.1. Genomics 1995, 26, 423–425. [Google Scholar] [CrossRef]
  61. Ren, H.; Stiles, G.L. Separate Promoters in the Human A1 Adenosine Receptor Gene Direct the Synthesis of Distinct Messenger RNAs That Regulate Receptor Abundance. Mol. Pharmacol. 1995, 48, 975–980. [Google Scholar]
  62. Ren, H.; Stiles, G.L. Posttranscriptional MRNA Processing as a Mechanism for Regulation of Human A1 Adenosine Receptor Expression. Proc. Natl. Acad. Sci. USA 1994, 91, 4864–4866. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  63. Cunha, R.A. Neuroprotection by Adenosine in the Brain: From A1 Receptor Activation to A2A Receptor Blockade. Purinergic Signal. 2005, 1, 111–134. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. Svenningsson, P.; Hall, H.; Sedvall, G.; Fredholm, B.B. Distribution of Adenosine Receptors in the Postmortem Human Brain: An Extended Autoradiographic Study. Synapse 1997, 27, 322–335. [Google Scholar] [CrossRef]
  65. Tetzlaff, W.; Schubert, P.; Kreutzberg, G.W. Synaptic and Extrasynaptic Localization of Adenosine Binding Sites in the Rat Hippocampus. Neuroscience 1987, 21, 869–875. [Google Scholar] [CrossRef]
  66. Swanson, T.H.; Drazba, J.A.; Rivkees, S.A. Adenosine A1 Receptors Are Located Predominantly on Axons in the Rat Hippocampal Formation. J. Comp. Neurol. 1995, 363, 517–531. [Google Scholar] [CrossRef]
  67. Ochiishi, T.; Chen, L.; Yukawa, A.; Saitoh, Y.; Sekino, Y.; Arai, T.; Nakata, H.; Miyamoto, H. Cellular Localization of Adenosine A1 Receptors in Rat Forebrain: Immunohistochemical Analysis Using Adenosine A1 Receptor-Specific Monoclonal Antibody. J. Comp. Neurol. 1999, 411, 301–316. [Google Scholar] [CrossRef]
  68. Rebola, N.; Pinheiro, P.C.; Oliveira, C.R.; Malva, J.O.; Cunha, R.A. Subcellular Localization of Adenosine A1 Receptors in Nerve Terminals and Synapses of the Rat Hippocampus. Brain Res. 2003, 987, 49–58. [Google Scholar] [CrossRef] [Green Version]
  69. Duc, N.M.; Kim, H.R.; Chung, K.Y. Recent Progress in Understanding the Conformational Mechanism of Heterotrimeric g Protein Activation. Biomol. Ther. 2017, 25, 4–11. [Google Scholar] [CrossRef] [Green Version]
  70. Bünemann, M.; Frank, M.; Lohse, M.J. Gi Protein Activation in Intact Cells Involves Subunit Rearrangement Rather than Dissociation. Proc. Natl. Acad. Sci. USA 2003, 100, 16077–16082. [Google Scholar] [CrossRef] [Green Version]
  71. Moreira, I.S. Structural Features of the G-Protein/GPCR Interactions. Biochim. Biophys. Acta Gen. Subj. 2014, 1840, 16–33. [Google Scholar] [CrossRef]
  72. Munshi, R.; Pang, I.H.; Sternweis, P.C.; Linden, J. A1 Adenosine Receptors of Bovine Brain Couple to Guanine Nucelotide-Binding Proteins G(I1), G(I2), and G(O). J. Biol. Chem. 1991, 266, 22285–22289. [Google Scholar] [PubMed]
  73. Wise, A.; Sheehan, M.; Rees, S.; Lee, M.; Milligan, G. Comparative Analysis of the Efficacy of A1 Adenosine Receptor Activation of G(i/o)α G Proteins Following Coexpression of Receptor and G Protein and Expression of A1 Adenosine Receptor-G(i/o)α Fusion Proteins. Biochemistry 1999, 38, 2272–2278. [Google Scholar] [CrossRef] [PubMed]
  74. Jiang, M.; Bajpayee, N.S. Molecular Mechanisms of Go Signaling. Neurosignals 2009, 17, 23–41. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  75. Cordeaux, Y.; Ijzerman, A.P.; Hill, S.J. Coupling of the Human A 1 Adenosine Receptor to Different Heterotrimeric G Proteins: Evidence for Agonist-Specific G Protein Activation. Br. J. Pharmacol. 2004, 143, 705–714. [Google Scholar] [CrossRef] [Green Version]
  76. Sebastião, A.M.; Ribeiro, J.A. Adenosine Receptors and the Central Nervous System. In Handbook of Experimental Pharmacology; Springer: Berlin/Heidelberg, Germany, 2009; Volume 193, pp. 471–534. [Google Scholar]
  77. Daniel, P.B.; Walker, W.H.; Habener, J.F. Cyclic amp signaling and gene regulation. Annu. Rev. Nutr. 1998, 18, 353–383. [Google Scholar] [CrossRef]
  78. Kobayashi, I.; Shibasaki, H.; Takahashi, K.; Tohyama, K.; Kurachi, Y.; Ito, H.; Ui, M.; Katada, T. Purification and Characterization of Five Different Alpha Subunits of Guanine-Nucleotide-Binding Proteins in Bovine Brain Membranes. Their Physiological Properties Concerning the Activities of Adenylate Cyclase and Atrial Muscarinic K+ Channels. Eur. J. Biochem. 1990, 191, 499–506. [Google Scholar] [CrossRef]
  79. Wong, Y.H.; Conklin, B.R.; Bourne, H.R. Gz-Mediated Hormonal Inhibition of Cyclic AMP Accumulation. Science (80-) 1992, 255, 339–342. [Google Scholar] [CrossRef]
  80. Putney, J.W.; Tomita, T. Phospholipase C Signaling and Calcium Influx. Adv. Biol. Regul. 2012, 52, 152–164. [Google Scholar] [CrossRef] [Green Version]
  81. Hisatsune, C.; Nakamura, K.; Kuroda, Y.; Nakamura, T.; Mikoshiba, K. Amplification of Ca2+ Signaling by Diacylglycerol-Mediated Inositol 1,4,5-Trisphosphate Production. J. Biol. Chem. 2005, 280, 11723–11730. [Google Scholar] [CrossRef] [Green Version]
  82. Suh, B.C.; Hille, B. Regulation of Ion Channels by Phosphatidylinositol 4,5-Bisphosphate. Curr. Opin. Neurobiol. 2005, 15, 370–378. [Google Scholar] [CrossRef]
  83. Gerwins, P.; Fredholm, B.B. ATP and Its Metabolite Adenosine Act Synergistically to Mobilize Intracellular Calcium via the Formation of Inositol 1,4,5-Trisphosphate in a Smooth Muscle Cell Line. J. Biol. Chem. 1992, 267, 16081–16087. [Google Scholar]
  84. Gerwins, P.; Fredholm, B.B. Activation of Adenosine A1 and Bradykinin Receptors Increases Protein Kinase C and Phospholipase D Activity in Smooth Muscle Cells. Naunyn. Schmiedebergs. Arch. Pharmacol. 1995, 351, 186–193. [Google Scholar] [CrossRef] [PubMed]
  85. Freund, S.; Ungerer, M.; Lohse, M.J. A1 Adenosine Receptors Expressed in CHO-Cells Couple to Adenylyl Cyclase and to Phospholipase C. Naunyn. Schmiedebergs. Arch. Pharmacol. 1994, 350, 49–56. [Google Scholar] [CrossRef] [PubMed]
  86. Iredale, P.A.; Alexander, S.P.H.; Hill, S.J. Coupling of a Transfected Human Brain A1 Adenosine Receptor in CHO-K1 Cells to Calcium Mobilisation via a Pertussis Toxin-Sensitive Mechanism. Br. J. Pharmacol. 1994, 111, 1252–1256. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  87. Dickenson, J.M.; Hill, S.J. Involvement of G-Protein Βγ Subunits in Coupling the Adenosine A1 Receptor to Phospholipase C in Transfected CHO Cells. Eur. J. Pharmacol. 1998, 355, 85–93. [Google Scholar] [CrossRef]
  88. Sternweis, P.C.; Smrcka, A.V. G Proteins in Signal Transduction: The Regulation of Phospholipase C. Ciba Found. Symp. 1993, 176, 96–111. [Google Scholar] [PubMed]
  89. Park, D.; Jhon, D.Y.; Lee, C.W.; Lee, K.H. Sue Goo Rhee. Activation of Phospholipase C Isozymes by G Protein Βγ Subunits. J. Biol. Chem. 1993, 268, 4573–4576. [Google Scholar]
  90. Hill, S.J.; Kendall, D.A. Studies on the Adenosine-receptor Mediating the Augmentation of Histamine-induced Inositol Phospholipid Hydrolysis in Guinea-pig Cerebral Cortex. Br. J. Pharmacol. 1987, 91, 661–669. [Google Scholar] [CrossRef] [Green Version]
  91. El-Etr, M.; Cordier, J.; Glowinski, J.; Premont, J. A Neuroglial Cooperativity Is Required for the Potentiation by 2-Chloroadenosine of the Muscarinic-Sensitive Phospholipase C in the Striatum. J. Neurosci. 1989, 9, 1473–1480. [Google Scholar] [CrossRef] [Green Version]
  92. Kendall, D.A.; Hill, S.J. Adenosine Inhibition of Histamine-Stimulated Inositol Phospholipid Hydrolysis in Mouse Cerebral Cortex. J. Neurochem. 1988, 50, 497–502. [Google Scholar] [CrossRef]
  93. Cascalheira, J.F.; Sebastião, A.M. Adenosine A1 Receptor Activation Inhibits Basal Accumulation of Inositol Phosphates in Rat Hippocampus. Pharmacol. Toxicol. 1998, 82, 189–192. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  94. Cascalheira, J.F.; Sebastião, A.M.; Ribeiro, J.A. Pertussis Toxin-Sensitive G Proteins Mediate the Inhibition of Basal Phosphoinositide Metabolism Caused by Adenosine A1 Receptors in Rat Hippocampal Slices. Neurochem. Res. 2002, 27, 1707–1711. [Google Scholar] [CrossRef] [PubMed]
  95. Segal, M. Intracellular Analysis of a Postsynaptic Action of Adenosine in the Rat Hippocampus. Eur. J. Pharmacol. 1982, 79, 193–199. [Google Scholar] [CrossRef]
  96. Trussell, L.O.; Jackson, M.B. Adenosine-Activated Potassium Conductance in Cultured Striatal Neurons. Proc. Natl. Acad. Sci. USA 1985, 82, 4857–4861. [Google Scholar] [CrossRef] [Green Version]
  97. Gerber, U.; Greene, R.W.; Haas, H.L.; Stevens, D.R. Characterization of Inhibition Mediated by Adenosine in the Hippocampus of the Rat in Vitro. J. Physiol. 1989, 417, 567–578. [Google Scholar] [CrossRef]
  98. Clark, B.D.; Kurth-Nelson, Z.L.; Newman, E.A. Adenosine-Evoked Hyperpolarization of Retinal Ganglion Cells Is Mediated by G-Protein-Coupled Inwardly Rectifying K+ and Small Conductance Ca2+-Activated K+ Channel Activation. J. Neurosci. 2009, 29, 11237–11245. [Google Scholar] [CrossRef] [Green Version]
  99. Rotermund, N.; Winandy, S.; Fischer, T.; Schulz, K.; Fregin, T.; Alstedt, N.; Buchta, M.; Bartels, J.; Carlström, M.; Lohr, C.; et al. Adenosine A 1 Receptor Activates Background Potassium Channels and Modulates Information Processing in Olfactory Bulb Mitral Cells. J. Physiol. 2018, 596, 717–733. [Google Scholar] [CrossRef] [Green Version]
  100. Trussell, L.O.; Jackson, M.B. Dependence of an Adenosine-Activated Potassium Current on a GTP-Binding Protein in Mammalian Central Neurons. J. Neurosci. 1987, 7, 3306–3316. [Google Scholar] [CrossRef] [Green Version]
  101. Thompson, S.M.; Haas, H.L.; Gähwiler, B.H. Comparison of the Actions of Adenosine at Pre- and Postsynaptic Receptors in the Rat Hippocampus in Vitro. J. Physiol. 1992, 451, 347–363. [Google Scholar] [CrossRef] [Green Version]
  102. Lüscher, C.; Slesinger, P.A. Emerging Roles for G Protein-Gated Inwardly Rectifying Potassium (GIRK) Channels in Health and Disease. Nat. Rev. Neurosci. 2010, 11, 301–315. [Google Scholar] [CrossRef]
  103. Mark, M.D.; Herlitze, S. G-Protein Mediated Gating of Inward-Rectifier K+ Channels. Eur. J. Biochem. 2000, 267, 5830–5836. [Google Scholar] [CrossRef] [PubMed]
  104. Reuveny, E.; Slesinger, P.A.; Inglese, J.; Morales, J.M.; Iñiguez-Lluhi, J.A.; Lefkowitz, R.J.; Bourne, H.R.; Jan, Y.N.; Jan, L.Y. Activation of the Cloned Muscarinic Potassium Channel by G Protein Βγ Subunits. Nature 1994, 370, 143–146. [Google Scholar] [CrossRef] [PubMed]
  105. Huang, C.L.; Slesinger, P.A.; Casey, P.J.; Jan, Y.N.; Jan, L.Y. Evidence That Direct Binding of Gβγ to the GIRK1 G Protein-Gated Inwardly Rectifying K+ Channel Is Important for Channel Activation. Neuron 1995, 15, 1133–1143. [Google Scholar] [CrossRef] [Green Version]
  106. Leaney, J.L.; Milligan, G.; Tinker, A. The G Protein α Subunit Has a Key Role in Determining the Specificity of Coupling to, but Not the Activation of, G Protein-Gated Inwardly Rectifying K+ Channels. J. Biol. Chem. 2000, 275, 921–929. [Google Scholar] [CrossRef] [Green Version]
  107. Peleg, S.; Varon, D.; Ivanina, T.; Dessauer, C.W.; Dascal, N. Gαi Controls the Gating of the G Protein-Activated K+ Channel, GIRK. Neuron 2002, 33, 87–99. [Google Scholar] [CrossRef] [Green Version]
  108. Berlin, S.; Tsemakhovich, V.A.; Castel, R.; Ivanina, T.; Dessauer, C.W.; Keren-Raifman, T.; Dascal, N. Two Distinct Aspects of Coupling between Gα i Protein and G Protein-Activated K + Channel (GIRK) Revealed by Fluorescently Labeled Gα I3 Protein Subunits. J. Biol. Chem. 2011, 286, 33223–33235. [Google Scholar] [CrossRef] [Green Version]
  109. Keselman, I.; Fribourg, M.; Felsenfeld, D.P.; Logothetis, D.E. Mechanism of PLC-Mediated Kir3 Current Inhibition. Channels 2007, 1, 113–123. [Google Scholar] [CrossRef] [Green Version]
  110. Mao, J.; Wang, X.; Chen, F.; Wang, R.; Rojas, A.; Shi, Y.; Piao, H.; Jiang, C. Molecular Basis for the Inhibition of G Protein-Coupled Inward Rectifier K+ Channels by Protein Kinase C. Proc. Natl. Acad. Sci. USA 2004, 101, 1087–1092. [Google Scholar] [CrossRef] [Green Version]
  111. Li, H.; Henry, J.L. Adenosine-Induced Hyperpolarization Is Depressed by Glibenclamide in Rat CA1 Neurones. Neuroreport 1992, 3, 1113–1116. [Google Scholar] [CrossRef]
  112. Andoh, T.; Ishiwa, D.; Kamiya, Y.; Echigo, N.; Goto, T.; Yamada, Y. A1 Adenosine Receptor-Mediated Modulation of Neuronal ATP-Sensitive K Channels in Rat Substantia Nigra. Brain Res. 2006, 1124, 55–61. [Google Scholar] [CrossRef]
  113. Sun, H.S.; Feng, Z.P. Neuroprotective Role of ATP-Sensitive Potassium Channels in Cerebral Ischemia. Acta Pharmacol. Sin. 2013, 34, 24–32. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  114. Kirsch, G.E.; Codina, J.; Birnbaumer, L.; Brown, A.M. Coupling of ATP-Sensitive K+ Channels to A1 Receptors by G Proteins in Rat Ventricular Myocytes. Am. J. Physiol. Hear. Circ. Physiol. 1990, 259, H820–H826. [Google Scholar] [CrossRef] [PubMed]
  115. Terzic, A.; Tung, R.T.; Inanobe, A.; Katada, T.; Kurachi, Y. G Proteins Activate ATP-Sensitive K+ Channels by Antagonizing ATP-Dependent Gating. Neuron 1994, 12, 885–893. [Google Scholar] [CrossRef]
  116. Hu, K.; Li, G.R.; Nattel, S. Adenosine-Induced Activation of ATP-Sensitive K+ Channels in Excised Membrane Patches Is Mediated by PKC. Am. J. Physiol. Hear. Circ. Physiol. 1999, 276, H488–H495. [Google Scholar] [CrossRef] [Green Version]
  117. Light, P.E.; Bladen, C.; Winkfein, R.J.; Walsh, M.P.; French, R.J. Molecular Basis of Protein Kinase C-Induced Activation of ATP-Sensitive Potassium Channels. Proc. Natl. Acad. Sci. USA 2000, 97, 9058–9063. [Google Scholar] [CrossRef] [Green Version]
  118. Mironov, S.L.; Langohr, K.; Richter, D.W. A1 Adenosine Receptors Modulate Respiratory Activity of the Neonatal Mouse via the CAMP-Mediated Signaling Pathway. J. Neurophysiol. 1999, 81, 247–255. [Google Scholar] [CrossRef] [Green Version]
  119. Faber, E.S.L. Functions and Modulation of Neuronal SK Channels. Cell Biochem. Biophys. 2009, 55, 127–139. [Google Scholar] [CrossRef]
  120. Enyedi, P.; Czirják, G. Molecular Background of Leak K+ Currents: Two-Pore Domain Potassium Channels. Physiol. Rev. 2010, 90, 559–605. [Google Scholar] [CrossRef] [Green Version]
  121. Mathie, A. Neuronal Two-Pore-Domain Potassium Channels and Their Regulation by G Protein-Coupled Receptors. J. Physiol. 2007, 578, 377–385. [Google Scholar] [CrossRef]
  122. Concas, A.; Santoro, G.; Mascia, M.P.; Maciocco, E.; Dazzi, L.; Ongini, E.; Biggic, G. Anticonvulsant Doses of 2-Chloro-N6-Cyclopentyladenosine, an Adenosine A1 Receptor Agonist, Reduce GABAergic Transmission in Different Areas of the Mouse Brain. J. Pharmacol. Exp. Ther. 1993, 267, 844–851. [Google Scholar]
  123. Rombo, D.M.; Dias, R.B.; Duarte, S.T.; Ribeiro, J.A.; Lamsa, K.P.; Sebastiaõ, A.M. Adenosine A1 Receptor Suppresses Tonic GABAA Receptor Currents in Hippocampal Pyramidal Cells and in a Defined Subpopulation of Interneurons. Cereb. Cortex 2016, 26, 1081–1095. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  124. Rombo, D.M.; Ribeiro, J.A.; Sebastião, A.M. Hippocampal GABAergic Transmission: A New Target for Adenosine Control of Excitability. J. Neurochem. 2016, 139, 1056–1070. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  125. Südhof, T.C. Calcium Control of Neurotransmitter Release. Cold Spring Harb. Perspect. Biol. 2012, 4, a011353. [Google Scholar] [CrossRef] [PubMed]
  126. Simms, B.A.; Zamponi, G.W. Neuronal Voltage-Gated Calcium Channels: Structure, Function, and Dysfunction. Neuron 2014, 82, 24–45. [Google Scholar] [CrossRef] [Green Version]
  127. MacDonald, R.L.; Skerritt, J.H.; Werz, M.A. Adenosine Agonists Reduce Voltage-dependent Calcium Conductance of Mouse Sensory Neurones in Cell Culture. J. Physiol. 1986, 370, 75–90. [Google Scholar] [CrossRef] [Green Version]
  128. Kasai, H.; Aosaki, T. Modulation of Ca-Channel Current by an Adenosine Analog Mediated by a GTP-Binding Protein in Chick Sensory Neurons. Pflügers Arch. Eur. J. Physiol. 1989, 414, 145–149. [Google Scholar] [CrossRef]
  129. Zhu, Y.; Ikeda, S.R. Adenosine Modulates Voltage-Gated Ca2+ Channels in Adult Rat Sympathetic Neurons. J. Neurophysiol. 1993, 70, 610–620. [Google Scholar] [CrossRef]
  130. Schubert, P.; Heinemann, U.; Kolb, R. Differential Effect of Adenosine on Pre- and Postsynaptic Calcium Fluxes. Brain Res. 1986, 376, 382–386. [Google Scholar] [CrossRef]
  131. Wu, L.-G.; Saggau, P. Adenosine Inhibits Evoked Synaptic Transmission Primarily by Reducing Presynaptic Calcium Influx in Area CA1 of Hippocampus. Neuron 1994, 12, 1139–1148. [Google Scholar] [CrossRef]
  132. Gundlfinger, A.; Bischofberger, J.; Johenning, F.W.; Torvinen, M.; Schmitz, D.; Breustedt, J. Adenosine Modulates Transmission at the Hippocampal Mossy Fibre Synapse via Direct Inhibition of Presynaptic Calcium Channels. J. Physiol. 2007, 582, 263–277. [Google Scholar] [CrossRef]
  133. Ambrósio, A.F.; Malva, J.O.; Carvalho, A.P.; Carvalho, C.M. Inhibition of N-, P/Q- and Other Types of Ca2+ Channels in Rat Hippocampal Nerve Terminals by the Adenosine A1 Receptor. Eur. J. Pharmacol. 1997, 340, 301–310. [Google Scholar] [CrossRef]
  134. Dolphin, A.C.; Prestwich, S.A. Pertussis Toxin Reverses Adenosine Inhibition of Neuronal Glutamate Release. Nature 1985, 316, 148–150. [Google Scholar] [CrossRef] [PubMed]
  135. Tedford, H.W.; Zamponi, G.W. Direct G Protein Modulation of Cav2 Calcium Channels. Pharmacol. Rev. 2006, 58, 837–862. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  136. Herlitze, S.; Garcla, D.E.; Mackle, K.; Hille, B.; Scheuer, T.; Catterall, W.A. Modulation of Ca2+ Channels by G-Protein Βγ Subunits. Nature 1996, 380, 258–262. [Google Scholar] [CrossRef] [PubMed]
  137. Ikeda, S.R. Voltage-Dependent Modulation of N-Type Calcium Channels by G-Protein Βγ Subunits. Nature 1996, 380, 255–258. [Google Scholar] [CrossRef] [PubMed]
  138. Zamponi, G.W.; Bourinet, E.; Nelson, D.; Nargeot, J.; Snutch, T.P. Crosstalk between G Proteins and Protein Kinase C Mediated by the Calcium Channel Α1 Subunit. Nature 1997, 385, 442–446. [Google Scholar] [CrossRef] [PubMed]
  139. Huang, J.; Zamponi, G.W. Regulation of Voltage Gated Calcium Channels by GPCRs and Post-Translational Modification. Curr. Opin. Pharmacol. 2017, 32, 1–8. [Google Scholar] [CrossRef]
  140. Hamid, J.; Nelson, D.; Spaetgens, R.; Dubel, S.J.; Snutch, T.P.; Zamponi, G.W. Identification of an Integration Center for Cross-Talk between Protein Kinase C and G Protein Modulation of N-Type Calcium Channels. J. Biol. Chem. 1999, 274, 6195–6202. [Google Scholar] [CrossRef] [Green Version]
  141. Wu, L.; Bauer, C.S.; Zhen, X.; Xie, C.; Yang, J. Dual Regulation of Voltage-Gated Calcium Channels by PtdIns(4,5)P2. Nature 2002, 419, 947–952. [Google Scholar] [CrossRef]
  142. Kaneko, S.; Akaike, A.; Satoh, M. Differential Regulation of N- and Q-Type Ca2+ Channels by Cyclic Nucleotides and G-Proteins. Life Sci. 1998, 62, 1543–1574. [Google Scholar] [CrossRef]
  143. Wang, S.; Kurada, L.; Cilz, N.I.; Chen, X.; Xiao, Z.; Dong, H.; Lei, S. Adenosinergic Depression of Glutamatergic Transmission in the Entorhinal Cortex of Juvenile Rats via Reduction of Glutamate Release Probability and the Number of Releasable Vesicles. PLoS ONE 2013, 8, e62185. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  144. Scanziani, M.; Capogna, M.; Gähwiler, B.H.; Thompson, S.M. Presynaptic Inhibition of Miniature Excitatory Synaptic Currents by Baclofen and Adenosine in the Hippocampus. Neuron 1992, 9, 919–927. [Google Scholar] [CrossRef]
  145. Scholz, K.P.; Miller, R.J. Inhibition of Quantal Transmitter Release in the Absence of Calcium Influx by a G Protein-Linked Adenosine Receptor at Hippocampal Synapses. Neuron 1992, 8, 1139–1150. [Google Scholar] [CrossRef]
  146. Bouron, A. Modulation of Spontaneous Quantal Release of Neurotransmitters in the Hippocampus. Prog. Neurobiol. 2001, 63, 613–635. [Google Scholar] [CrossRef]
  147. Bouron, A. Adenosine Suppresses Protein Kinase A- and C-Induced Enhancement of Glutamate Release in the Hippocampus. Eur. J. Neurosci. 1999, 11, 4446–4450. [Google Scholar] [CrossRef]
  148. Betke, K.M.; Wells, C.A.; Hamm, H.E. GPCR Mediated Regulation of Synaptic Transmission. Prog. Neurobiol. 2012, 96, 304–321. [Google Scholar] [CrossRef] [Green Version]
  149. Blackmer, T.; Larsen, E.C.; Takahashi, M.; Martin, T.F.J.; Alford, S.; Hamm, H.E. G Protein Βγ Subunit-Mediated Presynaptic Inhibition: Regutation of Exocytotic Fusion Downstream of Ca2+ Entry. Science (80-) 2001, 292, 293–297. [Google Scholar] [CrossRef]
  150. De Mendonça, A.; Sebastião, A.M.; Ribeiro, J.A. Inhibition of NMDA Receptor-Mediated Currents in Isolated Rat Hippocampal Neurones by Adenosine A1 Receptor Activation. Neuroreport 1995, 6, 1097–1100. [Google Scholar] [CrossRef]
  151. Pliássova, A.; Henriques, M.; Silva, H.B.; Agostinho, P.; Cunha, R.A.; Ferreira, S.G. Control of NMDA Receptor-Mediated Currents by Adenosine A 1 and A 2A Receptors Within the Basolateral Amygdala. J. Caffeine Adenosine Res. 2020, 10, 61–70. [Google Scholar] [CrossRef]
  152. Furukawa, H.; Singh, S.K.; Mancusso, R.; Gouaux, E. Subunit Arrangement and Function in NMDA Receptors. Nature 2005, 438, 185–192. [Google Scholar] [CrossRef]
  153. Lutzu, S.; Castillo, P.E. Modulation of NMDA Receptors by G-Protein-Coupled Receptors: Role in Synaptic Transmission, Plasticity and Beyond. Neuroscience 2020. [Google Scholar] [CrossRef] [PubMed]
  154. Yang, K.; Jackson, M.F.; MacDonald, J.F. Recent Progress in Understanding Subtype Specific Regulation of NMDA Receptors by G Protein Coupled Receptors (GPCRs). Int. J. Mol. Sci. 2014, 15, 3003–3024. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  155. Skeberdis, V.A.; Chevaleyre, V.; Lau, C.G.; Goldberg, J.H.; Pettit, D.L.; Suadicani, S.O.; Lin, Y.; Bennett, M.V.L.; Yuste, R.; Castillo, P.E.; et al. Protein Kinase A Regulates Calcium Permeability of NMDA Receptors. Nat. Neurosci. 2006, 9, 501–510. [Google Scholar] [CrossRef] [PubMed]
  156. Aman, T.K.; Maki, B.A.; Ruffino, T.J.; Kasperek, E.M.; Popescu, G.K. Separate Intramolecular Targets for Protein Kinase A Control N-Methyl-D-Aspartate Receptor Gating and Ca2+ Permeability. J. Biol. Chem. 2014, 289, 18805–18817. [Google Scholar] [CrossRef] [Green Version]
  157. Chen, L.; Mae Huang, L.Y. Protein Kinase C Reduces Mg2+ Block of NMDA-Receptor Channels as a Mechanism of Modulation. Nature 1992, 356, 521–523. [Google Scholar] [CrossRef]
  158. Lan, J.Y.; Skeberdis, V.A.; Jover, T.; Grooms, S.Y.; Lin, Y.; Araneda, R.C.; Zheng, X.; Bennett, M.V.L.; Zukin, R.S. Protein Kinase C Modulates NMDA Receptor Trafficking and Gating. Nat. Neurosci. 2001, 4, 382–390. [Google Scholar] [CrossRef]
  159. Rogawski, M.A. AMPA Receptors as a Molecular Target in Epilepsy Therapy. Acta Neurol. Scand. 2013, 127, 9–18. [Google Scholar] [CrossRef] [Green Version]
  160. Wang, J.Q.; Guo, M.L.; Jin, D.Z.; Xue, B.; Fibuch, E.E.; Mao, L.M. Roles of Subunit Phosphorylation in Regulating Glutamate Receptor Function. Eur. J. Pharmacol. 2014, 728, 183–187. [Google Scholar] [CrossRef] [Green Version]
  161. Mao, L.; Wang, J.Q. Upregulation of AMPA Receptor GluA1 Phosphorylation by Blocking Adenosine A1 Receptors in the Male Rat Forebrain. Brain Behav. 2020, 10, e01543. [Google Scholar] [CrossRef]
  162. Di Angelantonio, S.; Bertollini, C.; Piccinin, S.; Rosito, M.; Trettel, F.; Pagani, F.; Limatola, C.; Ragozzino, D. Basal Adenosine Modulates the Functional Properties of AMPA Receptors in Mouse Hippocampal Neurons through the Activation of A1R A2AR and A3R. Front. Cell. Neurosci. 2015, 9, 409. [Google Scholar] [CrossRef] [Green Version]
  163. Stockwell, J.; Chen, Z.; Niazi, M.; Nosib, S.; Cayabyab, F.S. Protein Phosphatase Role in Adenosine A1 Receptor-Induced AMPA Receptor Trafficking and Rat Hippocampal Neuronal Damage in Hypoxia/Reperfusion Injury. Neuropharmacology 2016, 102, 254–265. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  164. Brust, T.B.; Cayabyab, F.S.; Zhou, N.; MacVicar, B.A. P38 Mitogen-Activated Protein Kinase Contributes to Adenosine A1 Receptor-Mediated Synaptic Depression in Area CA1 of the Rat Hippocampus. J. Neurosci. 2006, 26, 12427–12438. [Google Scholar] [CrossRef] [PubMed]
  165. Liu, Q.; Hofmann, P.A. Modulation of Protein Phosphatase 2a by Adenosine A1 Receptors in Cardiomyocytes: Role for P38 MAPK. Am. J. Physiol. Hear. Circ. Physiol. 2003, 285, H97–H103. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  166. Chen, Z.; Xiong, C.; Pancyr, C.; Stockwell, J.; Walz, W.; Cayabyab, F.S. Prolonged Adenosine A1 Receptor Activation in Hypoxia and Pial Vessel Disruption Focal Cortical Ischemia Facilitates Clathrin-Mediated AMPA Receptor Endocytosis and Long- Lasting Synaptic Inhibition in Rat Hippocampal CA3-CA1 Synapses: Differential Regula. J. Neurosci. 2014, 34, 9621–9643. [Google Scholar] [CrossRef] [Green Version]
  167. Morrison, D.K. MAP Kinase Pathways. Cold Spring Harb. Perspect. Biol. 2012, 4, a011254. [Google Scholar] [CrossRef]
  168. Schulte, G.; Fredholm, B.B. Signalling from Adenosine Receptors to Mitogen-Activated Protein Kinases. Cell. Signal. 2003, 15, 813–827. [Google Scholar] [CrossRef]
  169. Robinson, A.J.; Dickenson, J.M. Regulation of P42/P44 MAPK and P38 MAPK by the Adenosine A1 Receptor in DDT1MF-2 Cells. Eur. J. Pharmacol. 2001, 413, 151–161. [Google Scholar] [CrossRef]
  170. Brust, T.B.; Cayabyab, F.S.; MacVicar, B.A. C-Jun N-Terminal Kinase Regulates Adenosine A1 Receptor-Mediated Synaptic Depression in the Rat Hippocampus. Neuropharmacology 2007, 53, 906–917. [Google Scholar] [CrossRef]
  171. Faure, M.; Voyno-Yasenetskaya, T.A.; Bourne, H.R. CAMP and Βγ Subunits of Heterotrimeric G Proteins Stimulate the Mitogen- Activated Protein Kinase Pathway in COS-7 Cells. J. Biol. Chem. 1994, 269, 7851–7854. [Google Scholar]
  172. Dickenson, J.M.; Blank, J.L.; Hill, S.J. Human Adenosine A1 Receptor and P2Y2-Purinoceptor-Mediated Activation of the Mitogen-Activated Protein Kinase Cascade in Transfected CHO Cells. Br. J. Pharmacol. 1998, 124, 1491–1499. [Google Scholar] [CrossRef] [Green Version]
  173. Hill, K.; Krugmann, S.; Andrews, S.R.; Coadwell, W.J.; Finan, P.; Welch, H.C.E.; Hawkins, P.T.; Stephens, L.R. Regulation of P-Rex1 by Phosphatidylinositol (3,4,5)-Trisphosphate and Gβγ Subunits. J. Biol. Chem. 2005, 280, 4166–4173. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  174. Minden, A.; Lin, A.; Claret, F.X.; Abo, A.; Karin, M. Selective Activation of the JNK Signaling Cascadeand C-Jun Transcriptional Activity by the Small GTPases Rac and Cdc42Hs. Cell 1995, 81, 1147–1157. [Google Scholar] [CrossRef] [Green Version]
  175. Liang, Y.C.; Huang, C.C.; Hsu, K.-S. A Role of P38 Mitogen-Activated Protein Kinase in Adenosine A Receptor-Mediated Synaptic Depotentiation in Area CA1 of the Rat Hippocampus. Mol. Brain 2008, 1, 13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  176. Jiang, W.; Van Cleemput, J.; Sheerin, A.H.; Ji, S.P.; Zhang, Y.; Saucier, D.M.; Corcoran, M.E.; Zhang, X. Involvement of Extracellular Regulated Kinase and P38 Kinase in Hippocampal Seizure Tolerance. J. Neurosci. Res. 2005, 81, 581–588. [Google Scholar] [CrossRef]
  177. Nateri, A.S.; Raivich, G.; Gebhardt, C.; Da Costa, C.; Naumann, H.; Vreugdenhil, M.; Makwana, M.; Brandner, S.; Adams, R.H.; Jefferys, J.G.R.; et al. ERK Activation Causes Epilepsy by Stimulating NMDA Receptor Activity. EMBO J. 2007, 26, 4891–4901. [Google Scholar] [CrossRef]
  178. Pernice, H.F.; Schieweck, R.; Kiebler, M.A.; Popper, B. MTOR and MAPK: From Localized Translation Control to Epilepsy. BMC Neurosci. 2016, 17, 73. [Google Scholar] [CrossRef] [Green Version]
  179. Prast, H.; Philippu, A. Nitric Oxide as Modulator of Neuronal Function. Prog. Neurobiol. 2001, 64, 51–68. [Google Scholar] [CrossRef]
  180. Garthwaite, J. Concepts of Neural Nitric Oxide-Mediated Transmission. Eur. J. Neurosci. 2008, 27, 2783–2802. [Google Scholar] [CrossRef] [Green Version]
  181. Serpa, A.; Sebastião, A.M.; Cascalheira, J.F. Modulation of CGMP Accumulation by Adenosine A1 Receptors at the Hippocampus: Influence of CGMP Levels and Gender. Eur. J. Pharmacol. 2014, 744, 83–90. [Google Scholar] [CrossRef]
  182. Pinto, I.; Serpa, A.; Sebastião, A.M.; Cascalheira, J.F. The Role of CGMP on Adenosine A1 Receptor-Mediated Inhibition of Synaptic Transmission at the Hippocampus. Front. Pharmacol. 2016, 7, 103. [Google Scholar] [CrossRef] [Green Version]
  183. Sterin-Borda, L.; Gómez, R.M.; Borda, E. Role of Nitric Oxide/Cyclic GMP in Myocardial Adenosine A1 Receptor-Inotropic Response. Br. J. Pharmacol. 2002, 135, 444–450. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  184. Serasanambati, M.; Chilakapati, S.R. Function of Nuclear Factor Kappa B (NF-KB) in Human Diseases-A Review. South Indian J. Biol. Sci. 2016, 2, 368–387. [Google Scholar] [CrossRef]
  185. Basheer, R.; Rainnie, D.G.; Porkka-Heiskanen, T.; Ramesh, V.; McCarley, R.W. Adenosine, Prolonged Wakefulness, and A1-Activated NF-ΚB DNA Binding in the Basal Forebrain of the Rat. Neuroscience 2001, 104, 731–739. [Google Scholar] [CrossRef]
  186. Nie, Z.; Mei, Y.; Ford, M.; Rybak, L.; Marcuzzi, A.; Ren, H.; Stiles, G.L.; Ramkumar, V. Oxidative Stress Increases A1 Adenosine Receptor Expression by Activating Nuclear Factor ΚB. Mol. Pharmacol. 1998, 53, 663–669. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  187. Liu, A.M.F.; Wong, Y.H. G 16 -Mediated Activation of Nuclear Factor ΚB by the Adenosine A 1 Receptor Involves c-Src, Protein Kinase C., and ERK Signaling. J. Biol. Chem. 2004, 279, 53196–53204. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  188. Amatruda, T.T.; Steele, D.A.; Slepak, V.Z.; Simon, M.I. Gα16, a G Protein α Subunit Specifically Expressed in Hematopoietic Cells. Proc. Natl. Acad. Sci. USA 1991, 88, 5587–5591. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  189. Kaltschmidt, B.; Widera, D.; Kaltschmidt, C. Signaling via NF-ΚB in the Nervous System. Biochim. Biophys. Acta Mol. Cell Res. 2005, 1745, 287–299. [Google Scholar] [CrossRef] [Green Version]
  190. Lubin, F.D.; Ren, Y.; Xu, X.; Anderson, A.E. Nuclear Factor-ΚB Regulates Seizure Threshold and Gene Transcription Following Convulsant Stimulation. J. Neurochem. 2007, 103, 1381–1395. [Google Scholar] [CrossRef]
  191. Di, Q.; Yu, N.; Liu, H.; Hu, Y.; Jiang, Y.; Yan, Y.K.; Zhang, Y.F.; Zhang, Y.D. Nuclear Factor-Kappa B Activity Regulates Brain Expression of P-Glycoprotein in the Kainic Acid-Induced Seizure Rats. Mediat. Inflamm. 2011, 2011. [Google Scholar] [CrossRef]
  192. Marini, A.M.; Jiang, X.; Wu, X.; Tian, F.; Zhu, D.; Okagaki, P.; Lipsky, R.H. Role of Brain-Derived Neurotrophic Factor and NF-ΚB in Neuronal Plasticity and Survival: From Genes to Phenotype. Restor. Neurol. Neurosci. 2004, 22, 121–130. [Google Scholar]
  193. Yoon, H.; Oh, Y.T.; Lee, J.Y.; Choi, J.H.; Lee, J.H.; Baik, H.H.; Kim, S.S.; Choe, W.; Yoon, K.S.; Ha, J.; et al. Activation of AMP-Activated Protein Kinase by Kainic Acid Mediates Brain-Derived Neurotrophic Factor Expression through a NF-KappaB Dependent Mechanism in C6 Glioma Cells. Biochem. Biophys. Res. Commun. 2008, 371, 495–500. [Google Scholar] [CrossRef] [PubMed]
  194. Zhou, Q.; Zhu, S.; Guo, Y.; Lian, L.; Hu, Q.; Liu, X.; Xu, F.; Zhang, N.; Kang, H. Adenosine A1 Receptors Play an Important Protective Role Against Cognitive Impairment and Long-Term Potentiation Inhibition in a Pentylenetetrazol Mouse Model of Epilepsy. Mol. Neurobiol. 2018, 55, 3316–3327. [Google Scholar] [CrossRef]
  195. Suen, P.C.; Wu, K.; Levine, E.S.; Mount, H.T.J.; Xu, J.L.; Lin, S.Y.; Black, I.B. Brain-Derived Neurotrophic Factor Rapidly Enhances Phosphorylation of the Postsynaptic N-Methyl-D-Aspartate Receptor Subunit 1. Proc. Natl. Acad. Sci. USA 1997, 94, 8191–8195. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  196. Binder, D.K.; Croll, S.D.; Gall, C.M.; Scharfman, H.E. BDNF and Epilepsy: Too Much of a Good Thing? Trends Neurosci. 2001, 24, 47–53. [Google Scholar] [CrossRef]
  197. Iughetti, L.; Lucaccioni, L.; Fugetto, F.; Predieri, B.; Berardi, A.; Ferrari, F. Brain-Derived Neurotrophic Factor and Epilepsy: A Systematic Review. Neuropeptides 2018, 72, 23–29. [Google Scholar] [CrossRef] [PubMed]
  198. Malva, J.O.; Silva, A.P.; Cunha, R.A. Presynaptic Modulation Controlling Neuronal Excitability and Epileptogenesis: Role of Kainate, Adenosine and Neuropeptide Y Receptors. Neurochem. Res. 2003, 28, 1501–1515. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  199. Sosulina, L.; Schwesig, G.; Seifert, G.; Pape, H.C. Neuropeptide Y Activates a G-Protein-Coupled Inwardly Rectifying Potassium Current and Dampens Excitability in the Lateral Amygdala. Mol. Cell. Neurosci. 2008, 39, 491–498. [Google Scholar] [CrossRef]
Figure 1. Adenosine metabolism in the brain: intra-(IC) and extracellular (EC) catabolization of adenine nucleotides (ATP, ADP, AMP) by nucleotidases (NT) leads to formation of adenosine. Intracellularly, adenosine deaminase (ADA) breaks down adenosine to inosine and adenosine kinase (ADK) phosphorylates adenosine to AMP. Bidirectional transport of adenosine via equilibrative nucleoside transporters (ENT) equalizes the IC and EC adenosine concentrations.
Figure 1. Adenosine metabolism in the brain: intra-(IC) and extracellular (EC) catabolization of adenine nucleotides (ATP, ADP, AMP) by nucleotidases (NT) leads to formation of adenosine. Intracellularly, adenosine deaminase (ADA) breaks down adenosine to inosine and adenosine kinase (ADK) phosphorylates adenosine to AMP. Bidirectional transport of adenosine via equilibrative nucleoside transporters (ENT) equalizes the IC and EC adenosine concentrations.
Ijms 22 00320 g001
Figure 2. The G protein activation cycle: (1) in its inactive state, the α-subunit (Gα) binds guanosine diphosphate (GDP) and forms a heterotrimeric G protein complex with the β- and γ-subunits (Gβγ). (2) Binding of an agonist to a G-protein coupled receptor (GPCR) induces conformational changes. The outward movement of transmembrane helix 6 enables interaction of the GPCR with the heterotrimeric G proteins, catalyzing the exchange of GDP for GTP. (3) Gα and Gβγ then dissociate and interact with effectors. (4) Gα-induced hydrolyzation of GTP to GDP causes the G protein subunits to associate and return to their inactive state.
Figure 2. The G protein activation cycle: (1) in its inactive state, the α-subunit (Gα) binds guanosine diphosphate (GDP) and forms a heterotrimeric G protein complex with the β- and γ-subunits (Gβγ). (2) Binding of an agonist to a G-protein coupled receptor (GPCR) induces conformational changes. The outward movement of transmembrane helix 6 enables interaction of the GPCR with the heterotrimeric G proteins, catalyzing the exchange of GDP for GTP. (3) Gα and Gβγ then dissociate and interact with effectors. (4) Gα-induced hydrolyzation of GTP to GDP causes the G protein subunits to associate and return to their inactive state.
Ijms 22 00320 g002
Figure 3. Schematic representation of the signaling pathways involved in increased K+ permeability and hyperpolarizing effects of A1R activation. A1Rs activate G protein-coupled inwardly rectifying K+ (GIRK) channels directly via the G protein subunits (Gα and Gβγ) or indirectly by inhibiting PLC activity. A1Rs increase ATP-sensitive K+ (KATP) channel activity by inhibiting the AC/cAMP pathway or by both stimulating (via increased PKC) or inhibiting (via increased PIP2) the PLC pathway. A1R-induced IP3 stimulation activates small conductance Ca2+-activated K+ (SK) channels by increasing intracellular Ca2+ concentration. The pathway underlying activation of two-pore domain K+ (K2P) channels is unknown and therefore not presented here. AC: adenyl cyclase; cAMP: cyclic adenosine monophosphate; PKA: protein kinase A; PLC: phospholipase C; PIP2: phosphatidylinositol 4,5-bisphosphate; IP3: inositol 1,4,5-trisphosphate; DAG: diacylglycerol; PKC: phosphokinase C.
Figure 3. Schematic representation of the signaling pathways involved in increased K+ permeability and hyperpolarizing effects of A1R activation. A1Rs activate G protein-coupled inwardly rectifying K+ (GIRK) channels directly via the G protein subunits (Gα and Gβγ) or indirectly by inhibiting PLC activity. A1Rs increase ATP-sensitive K+ (KATP) channel activity by inhibiting the AC/cAMP pathway or by both stimulating (via increased PKC) or inhibiting (via increased PIP2) the PLC pathway. A1R-induced IP3 stimulation activates small conductance Ca2+-activated K+ (SK) channels by increasing intracellular Ca2+ concentration. The pathway underlying activation of two-pore domain K+ (K2P) channels is unknown and therefore not presented here. AC: adenyl cyclase; cAMP: cyclic adenosine monophosphate; PKA: protein kinase A; PLC: phospholipase C; PIP2: phosphatidylinositol 4,5-bisphosphate; IP3: inositol 1,4,5-trisphosphate; DAG: diacylglycerol; PKC: phosphokinase C.
Ijms 22 00320 g003
Figure 4. Schematic representation of the signaling pathways involved in the suppression of neurotransmission by adenosine A1 receptors (A1R). A1Rs suppress neurotransmitter release in a Ca2+-dependent way by inhibiting voltage-gated Ca2+ channels (VGCCs) via Gβγ. Additionally, VGCCs are inhibited through reduced PLC signaling resulting in reduced disinhibition by PKC and increased inhibition by PIP2. Inhibition of PKA activity by A1R also enhances PIP2-mediated inhibition of VGCCs. Through binding of Gβγ to SNARE proteins, A1Rs also suppress neurotransmitter release in a Ca2+-independent way. Postsynaptic NMDA (NMDAR) and AMPA receptor (AMPAR) function is negatively modulated by A1Rs through inhibition of PKA and PKC activity. AC: adenyl cyclase; cAMP: cyclic adenosine monophosphate; PKA: protein kinase A; PLC: phospholipase C; PIP2: phosphatidylinositol 4,5-bisphosphate; IP3: inositol 1,4,5-trisphosphate; DAG: diacylglycerol; PKC: phosphokinase C.
Figure 4. Schematic representation of the signaling pathways involved in the suppression of neurotransmission by adenosine A1 receptors (A1R). A1Rs suppress neurotransmitter release in a Ca2+-dependent way by inhibiting voltage-gated Ca2+ channels (VGCCs) via Gβγ. Additionally, VGCCs are inhibited through reduced PLC signaling resulting in reduced disinhibition by PKC and increased inhibition by PIP2. Inhibition of PKA activity by A1R also enhances PIP2-mediated inhibition of VGCCs. Through binding of Gβγ to SNARE proteins, A1Rs also suppress neurotransmitter release in a Ca2+-independent way. Postsynaptic NMDA (NMDAR) and AMPA receptor (AMPAR) function is negatively modulated by A1Rs through inhibition of PKA and PKC activity. AC: adenyl cyclase; cAMP: cyclic adenosine monophosphate; PKA: protein kinase A; PLC: phospholipase C; PIP2: phosphatidylinositol 4,5-bisphosphate; IP3: inositol 1,4,5-trisphosphate; DAG: diacylglycerol; PKC: phosphokinase C.
Ijms 22 00320 g004
Figure 5. Activation of MAPK pathways (highlighted in yellow), the guanyl cyclase pathway (highlighted in orange) and nuclear factor-κB (highlighted in purple) by the adenosine A1 receptor (A1R). AC: adenyl cyclase; cAMP: cyclic adenosine monophosphate; PKA: protein kinase A; PLC: phospholipase C; PIP2: phosphatidylinositol 4,5-bisphosphate; IP3: inositol 1,4,5-trisphosphate; DAG: diacylglycerol; PKC: phosphokinase C; CamKII: calmodulin-dependent protein kinase II; PI3K: phosphatidylinositol 3-kinase; PIP3: phosphatidylinositol 3,4,5-trisphosphate; JNK: c-Jun N-terminal kinase; ERK: extracellular signal-regulated kinase; p38 MAPK: p38 mitogen-activated protein kinase; NOS: nitric oxide synthase; NO: nitric oxide; sGC: soluble guanylyl cyclase; cGMP: cyclic guanosine monophosphate; PKG: protein kinase G; IKK: IκB kinase; NF-kB: nuclear factor-κB.
Figure 5. Activation of MAPK pathways (highlighted in yellow), the guanyl cyclase pathway (highlighted in orange) and nuclear factor-κB (highlighted in purple) by the adenosine A1 receptor (A1R). AC: adenyl cyclase; cAMP: cyclic adenosine monophosphate; PKA: protein kinase A; PLC: phospholipase C; PIP2: phosphatidylinositol 4,5-bisphosphate; IP3: inositol 1,4,5-trisphosphate; DAG: diacylglycerol; PKC: phosphokinase C; CamKII: calmodulin-dependent protein kinase II; PI3K: phosphatidylinositol 3-kinase; PIP3: phosphatidylinositol 3,4,5-trisphosphate; JNK: c-Jun N-terminal kinase; ERK: extracellular signal-regulated kinase; p38 MAPK: p38 mitogen-activated protein kinase; NOS: nitric oxide synthase; NO: nitric oxide; sGC: soluble guanylyl cyclase; cGMP: cyclic guanosine monophosphate; PKG: protein kinase G; IKK: IκB kinase; NF-kB: nuclear factor-κB.
Ijms 22 00320 g005
Figure 6. Overview of the pre- and postsynaptic targets of the adenosine A1 receptor (A1R) through which it mediates its main inhibitory neuromodulatory effects; hyperpolarization via activation of K+ channels and suppression of synaptic transmission via inhibition of voltage-gated Ca2+ channels (VGCCs) and proteins involved in exocytosis. AMPAR: AMPA receptor; NMDAR: NMDA receptor; GIRK: G protein-coupled inwardly rectifying K+ channel; KATP: ATP-sensitive K+ channel; SK: small conductance Ca2+-activated K+ channel; K2P: two-pore domain K+ channel.
Figure 6. Overview of the pre- and postsynaptic targets of the adenosine A1 receptor (A1R) through which it mediates its main inhibitory neuromodulatory effects; hyperpolarization via activation of K+ channels and suppression of synaptic transmission via inhibition of voltage-gated Ca2+ channels (VGCCs) and proteins involved in exocytosis. AMPAR: AMPA receptor; NMDAR: NMDA receptor; GIRK: G protein-coupled inwardly rectifying K+ channel; KATP: ATP-sensitive K+ channel; SK: small conductance Ca2+-activated K+ channel; K2P: two-pore domain K+ channel.
Ijms 22 00320 g006
Table 1. Changes in expression levels of A1Rs in chronic epilepsy.
Table 1. Changes in expression levels of A1Rs in chronic epilepsy.
Observations in TLE Patients
ChangeTissueDetection Method + ResultsRef.
Increased A1R expression in human refractory TLE patients -  Excised epileptic temporal lobe tissue refractory TLE patients (n = 5) Excised control temporal lobe tissue brain tumor patients (n = 6)-  Autoradiographic labeling of A1R with [3H]CHA
-  48% increase in A1R binding density
[44]
Decreased A1R expression in human refractory TLE patients -  Excised epileptic temporal lobe tissue refractory TLE patients (n = 15)
-  Post-mortem control temporal lobe tissue from non-epileptic subjects (n = 9)
-  Autoradiographic labeling of A1R with [3H]CHA
-  70% decrease in A1R binding density
[45]
Observations in chronic epilepsy models
ChangeAnimal modelTimeframeDetection method + resultsRef.
Decreased A1R expression in CA2/CA3 regions of epileptic rats -  Wistar rats
-  KA i.p. treatment
-  Hippocampal kindling
1–2 months after treatment-  Immunohistochemical labeling with A1R antibody
-  Near 100% loss of A1R immunoreactivity
-  Decrease in A1R immunoreactivity on stimulated but not on contralateral side of kindled animals
[46]
Decreased A1R expression in CA1/CA3 regions of epileptic rats -  S-D rats
-  KA i.p. treatment
30 days after treatment-  Autoradiographic labeling of A1R with [3H]CHA
-  70% decrease in A1R density in CA1, 40% decrease in CA3
-  related to neuronal degradation
[47]
Decreased A1R expression in hippocampal slices of epileptic rats -  Wistar rats
-  Amygdala kindling
3–4 weeks after treatment-  Autoradiographic labeling of A1R with [3H]R-PIA
-  Immunohistochemical labeling with A1R antibody
-  43% decrease in A1R binding density
[48]
Increased A1R expression in epileptic mice -  Balb/C mice
-  PTZ kindling (i.p.)
1–4 weeks after treatment-  Autoradiographic labeling of A1R with [3H]CHA
-  >20% increase in A1R binding
[49]
Increased A1R expression in medial entorhinal cortex slices of epileptic rats -  S-D rats
-  Hippocampal kindling
2 months after treatment-  qPCR
-  Immunohistochemical labeling with A1R antibody
-  378% increase in A1R mRNA
-  60% increase in A1R immunoreactivity
[50]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Spanoghe, J.; Larsen, L.E.; Craey, E.; Manzella, S.; Van Dycke, A.; Boon, P.; Raedt, R. The Signaling Pathways Involved in the Anticonvulsive Effects of the Adenosine A1 Receptor. Int. J. Mol. Sci. 2021, 22, 320. https://doi.org/10.3390/ijms22010320

AMA Style

Spanoghe J, Larsen LE, Craey E, Manzella S, Van Dycke A, Boon P, Raedt R. The Signaling Pathways Involved in the Anticonvulsive Effects of the Adenosine A1 Receptor. International Journal of Molecular Sciences. 2021; 22(1):320. https://doi.org/10.3390/ijms22010320

Chicago/Turabian Style

Spanoghe, Jeroen, Lars E. Larsen, Erine Craey, Simona Manzella, Annelies Van Dycke, Paul Boon, and Robrecht Raedt. 2021. "The Signaling Pathways Involved in the Anticonvulsive Effects of the Adenosine A1 Receptor" International Journal of Molecular Sciences 22, no. 1: 320. https://doi.org/10.3390/ijms22010320

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop